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Proposal Summary 
 
Mitochondrial disease is an umbrella term that encompasses many clinically, biochemically 
and genetically heterogeneous conditions, which develop as a consequence of impaired 
oxidative phosphorylation. The diagnosis of mitochondrial disease requires coordinated multi-
disciplinary input, starting with a high index of clinical suspicion and meticulous assessment, 
followed by systematic biochemical and genetic investigations. More recently, the advent of 
next generation sequencing has rapidly identified novel disease genes and mechanisms in 
many previously undiagnosed cases. However, the aspects of natural history, disease 
progression and prognostication associated with many of these genetic variants require further 
elucidation. Furthermore, genotype-specific treatment guidance and surveillance strategy for 
complications are lacking in a routine clinical setting. 
The MRC Mitochondrial Disease Patient Cohort (UK) is a national collaborative project 
initiated by three centres of NHS Highly Specialised Service for Rare Mitochondrial 
Disorders: Newcastle, London and Oxford. Newcastle is the largest centre and has enrolled 
over 55% of patients (~800), to date. My aim has been to utilise the longitudinal data 
collected for this national cohort database to facilitate deep phenotyping of common and rare 
genetic variants, investigate phenotype-genotype correlations and identify treatable 
complications of mitochondrial disease. In this thesis, I show that sudden adult death 
syndrome and severe intestinal pseudo-obstruction are two previously under-recognized 
clinical entities associated with the m.3243A>G mutation, the most common pathogenic 
heteroplasmic mitochondrial DNA mutation in adult patients. The significant implications of 
these findings for clinical practice are highlighted.  
Extrapyramidal movement disorders are identified in 5% of patients followed up in 
Newcastle. I sought to determine the spectrum of extrapyramidal movement disorders in 
children and adults, and interrogate the genotype-phenotype correlation that may provide 
screening guidance for generalists. 
Mutations in RMND1 (Required for Meiotic Nuclear Division protein 1) and YARS2 
(mitochondrial tyrosyl-tRNA synthetase) genes both result in combined mitochondrial 
respiratory chain deficiencies, but their clinical phenotypes are distinctive. Survival in patients 
with RMDN1 deficiency is influenced by the presence of kidney disease, as shown in the 
multi-centre collaborative study that I have drawn together. Myopathy, lactic acidosis and 
sideroblastic anaemia (MLASA) is a classic syndrome associated with mutations in YARS2. 
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However, such a syndromic presentation is not always evident in all patients, and I sought to 
demonstrate that cardio-respiratory insufficiency is a prominent, potentially treatable, 
complication in patients who harbour mutations in YARS2 without having the complete 
MLASA phenotype. 
Understanding the spectrum of clinical phenotypes and providing appropriate, accurate 
genetic counselling for heteroplasmic mitochondrial DNA point mutations is challenging 
under normal circumstances, but this is particularly difficult when the specific mutation is rare 
and phenotypic data are scant. I sought to perform a detailed analysis of patients harbouring 
the m.13094T>C mutation in MT-ND5. 
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Mitochondrial disease is one of the most common metabolic diseases with an estimated 
prevalence of 1 in 4300 (Gorman et al., 2015) and can affect all age groups from neonatal to 
adult onset. It is a collective term that encompasses a wide array of conditions that are 
biochemically, genetically and clinically heterogeneous. Currently, there remains no cure for 
mitochondrial disease, and the main focuses of management are monitoring for complications, 
supportive treatment and genetic counselling. Therefore, natural history studies and a better 
understanding of disease progression of individual genotypes are essential steps in improving 
the accuracy of prognostication, evaluating treatments and tailoring future therapeutic 
strategies. 
  
1.1 Mitochondrial molecular biology 
1.1.1 Origin 
The most prevailing hypothesis to explain the origin of mitochondria is the endosymbiosis 
theory, which was popularised by Lynn Margulis (married name Sagan, 1938-2011) (Sagan, 
1967). Essentially, the proposed theory suggests that an ancestor of eukaryotic cells (host cell) 
engulfed an aerobic prokaryote, which the latter became an endosymbiont (i.e., a cell living 
within another cell). The heterotrophic and anaerobic host benefited from endosymbionts that 
could undergo aerobic respiration and generate ATP more efficiently (Reece, 2011). Most of 
the genes encoding endosymbiont were transferred into the host nucleus over the course of 
formation of mitochondria (Dolezal et al., 2006). The phylogenetic studies subsequently 
provided evidence to show that mitochondria originated from the α-alpha proteobacteria and 
only arose once in evolution more than a billion years ago (Gray et al., 2001). Furthermore, 
most of the proteins that function in mitochondria carry short N-terminal targeting sequences 
that are highly conserved across the species (Dolezal et al., 2006).  
 
1.1.2 Mitochondrial structure and oxidative phosphorylation 
Mitochondria are cellular organelles found in all nucleated cells (except mature red blood cells) 
in humans. Each mitochondrion has two membranes (outer and inner), inter-membrane space 
and matrix. The mitochondrial matrix contains multiple copies of mitochondrial DNA 
(mtDNA) molecules and enzymes involved in various biochemical pathways. It is clear that 
mitochondria have many functions, but probably the most crucial one is to generate energy in 
the form ATPs (adenosine triphosphate) via oxidative phosphorylation using glucose and fatty 
acid as fuel. The oxidative phosphorylation system (OXPHOS) is located in the inner membrane 
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and it consists of five multimeric protein complexes: complex I (NADH:ubiquinone 
oxidoreductase), complex II (succinate:ubiquinone oxidoreductase), complex III 
(ubiquinol:cytochrome c oxidoreductase), complex IV (cytochrome c oxidase, COX) which are 
collectively called the mitochondrial respiratory chain and complex V (ATP synthase). In 
addition, there are two electron carriers (coenzyme Q10 and cytochrome c).  
In aerobic respiration, glucose is metabolised to pyruvate, which is then transported to the 
mitochondria and converted to acetyl-CoA followed by a series of chemical reactions called 
tricarboxylic acid (TCA or Kreb) cycle. The outcome of TCA cycle is the formation of carbon 
dioxide (CO2), reduced nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine 
dinucleotide (FADH2). The beta-oxidation of fatty acid produces FADH2 and acetyl-CoA 
which the latter enters the common TCA pathway (Figure 1) (Taylor and Turnbull, 2005). 
Electron transfer flavoprotein (ETF) transfers electrons from beta-oxidation to co-enzyme Q10 
via the ETF dehydrogenase (ETFDH). The mitochondrial respiratory chain oxidises both 
NADH and FADH2 and pumps the derived protons across the inner membrane to the inter-
membrane space creating an electrochemical gradient while at the same time coenzyme Q10 
and cytochrome c transfer the electrons to the molecule oxygen (O2) to form water. Complex 
V utilises this gradient to phosphorylate adenosine diphosphate (ADP) and produces ATP 
(Figure 2) (Schon et al., 2012). Anaerobic respiration is a much simpler pathway where 
pyruvate is converted to lactate generating four ATPs in the cytosol. This is of particular 
relevance as one of the major consequences associated with mitochondrial respiratory chain 
dysfunction is lactic acidosis. 
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Figure 1. Tricarboxylic acid cycle and beta-oxidation. ADP= adenosine diphosphate, 
ATP= adenosine triphosphate, ANT= adenine nucleotide translocator, CACT = carnitine-
acylcarnitine translocase, CoQ= coenzyme Q, CPT= carnitine palmitoyltransferase, DIC= 
dicarboxylate carrier, ETF= electron-transfer flavoprotein, ETF-DH= electron-transfer 
dehydrogenase, FAD= flavin adenine dinucleotide, FADH2= reduced FAD, NADH= reduced 
nicotinamide adenine dinucleotide, PDHC= pyruvate dehydrogenase complex, TCA= 
tricarboxylic acid. Reproduced from (Di Mauro and Schon, 2003) 
 
Figure 2. Mitochondrial electron transport chain (Complex I-IV) and ATP synthase 
(complex V). Electron transport between complexes is mediated by membrane-embedded 
ubiquinone (Q) and soluble cytochrome c. Complex I is the entry point for electrons from 
NADH, which are used to reduce Q to ubiquinol (QH2). QH2 is subsequently used by 
complex III to reduce cytochrome c in the intermembrane space (IMS), and complex IV uses 
cytochrome c to reduce molecular oxygen, which is the ultimate electron acceptor. For each 
NADH molecule oxidised, 10 protons are translocated across the membrane from the matrix 
to the IMS. Reproduced from (Sazanov, 2015) 
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1.1.2.1 Complex I 
Complex I, also known as NADH: ubiquinone oxidoreductase, is the largest complex in the 
mitochondrial respiratory chain. There are 45 subunits in the mammalian complex I of which 
14 core subunits (NDUFS1, NDUFV1, NDUFV2, NDUFS2, NDUFS3, NDUFS8, NDUFS7, 
ND1-6 and ND4L) are strictly conserved and shared across species; 31 accessory subunits 
have been acquired over the course of evolution (Sazanov, 2015; Zhu et al., 2016).  
Complex I is an L-shaped molecule with two arms; a hydrophilic peripheral arm (N module 
and Q module) and a hydrophobic membrane embedded (P module) arm. The peripheral arm 
consists of two functional modules (N module and Q module) and all of the necessary 
cofactors (one FMN, flavin mononucleotide; and eight iron-sulphur (Fe-S) clusters). The 
oxidisation of NADH occurs in the NDUFV1 of the N module followed by the transfer of 
electrons along a chain of Fe-S clusters to the terminal cluster (N2) and Q-module (Zhu et al., 
2016), where the ubiquinone is reduced to ubiquinol. The proton translocation activity in the 
membrane arm (P module) is triggered by the reduction of ubiquinone (Figure 3) (Wirth et 
al., 2016). All the core subunits in the membrane arm are encoded by the mtDNA. The core 
subunits are clearly involved in the bioenergetics function. The precise roles of individual 
accessory subunits are less well-characterized but are thought to be important in the assembly 
of complex I, maintenance of the structural stability and some of them may play other 
metabolic roles (Zhu et al., 2016). Using the gene editing tools (TALENS and 
CRISPR/Cas9), an Australian research group demonstrated 25 accessory subunits are required 
for assembly of a functional complex I and NDUFAB1 is an essential subunit for cell viability 
(Stroud et al., 2016). 
 
Figure 3. NADH oxidation, ubiquinone reduction and proton translocation in Complex 
I. Reproduced with permission from (Wirth et al., 2016) 
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The integration of subunits and formation of individual OXPHOS complexes are dependent 
on the specific assembly factors, and at least 13 assembly factors have been characterised in 
complex I (Giachin et al., 2016). Given the numbers of structural subunits and assembly 
factors in complex I, it is unsurprising that complex I deficiency is the most common 
biochemical defect causing mitochondrial disease (Kirby et al., 1999; Skladal et al., 2003a). 
 
1.1.2.2 Complex II 
Complex II (succinate: ubiquinone oxidoreductase), is the smallest enzymatic complex of 
OXPHOS which only comprises of four nuclear-encoded subunits (SDHA, SDHB, SDHC 
and SDHD). SDHA and SDHB make up the hydrophilic domain of the complex II while 
SDHC and SDHD are anchored to the inner membrane (Briere et al., 2005). SDHAF2 and 
SDHAF2 are the two known assembly factors of complex II.  
Complex II catalyses the oxidation of succinate to fumarate in the TCA cycle with the 
reduction of ubiquinone to ubiquinol (Rustin et al., 2002). It has a powerful reducing property 
and ability to trigger reverse electron flow through complex I, resulting in the production of 
NADH (Rustin et al., 2002). Mutations in the SDH subunits causing primary mitochondrial 
disease have been reported (Bourgeron et al., 1995; Alston et al., 2012; Jackson et al., 2014) 
but they are rare. Intriguingly, heterozygous mutations in the SDH subunits (SDHB, SDHC 
and SDHD) and assembly factors account for at least 15% of all paraganglioma and 
phaeochromocytoma (Baysal et al., 2002; Gill et al., 2010). The precise mechanism of SDH 
defect and the formation of specific neuro-endocrine tumours remains elusive although the 
activation of hypoxia-inducible factors involving in pseudo-hypoxia pathway has been 
implicated (Briere et al., 2005; Pasini and Stratakis, 2009).   
 
1.1.2.3 Ubiquinone 
A human isoform of ubiquinone, Coenzyme Q10 (CoQ10), is composed of a benzoquinone 
ring with ten isoprene units attached to it (Alcázar-Fabra et al., 2016). Most of CoQ is 
synthesised endogenously, but some of them are derived from the diet (Alcázar-Fabra et al., 
2016). Ubiquinone shuttles electrons from complexes I and II to complex III. In addition, it 
can also be reduced to ubiquinol (by receiving electrons) by other dehydrogenases that 
involve different metabolic pathways such as the electron transport flavoprotein 
dehydrogenases family (ETFDH) from fatty oxidation, dihydroorotate dehydrogenase that is 
involved in the pyrimidine nucleotide biosynthesis pathway and glycerol 3-phosphate 
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dehydrogenase that involves in the lipid metabolism (Alcázar-Fabra et al., 2016).  Primary 
ubiquinone deficiency is caused by mutations in the nuclear-encoded proteins involving in the 
CoQ biosynthesis pathway (Acosta et al., 2016). Secondary deficiency has been observed in 
other conditions as a consequence of either defect in mitochondrial DNA such as 
mitochondrial depletion syndrome, mitochondrial tRNA point mutation or fatty acid oxidation 
defect, for example, mutations in the ETFDH gene (Alcázar-Fabra et al., 2016). 
 
1.1.2.4 Complex III 
Mammalian complex III (ubiquinone: cytochrome c oxidoreductase) is a multi heteromeric 
enzyme that has 11 subunits, only one of them is encoded by mtDNA (MT-CYB). The number 
of subunits in complex III varies between species, but three of them are highly conserved: 
cyt b, cyt c1 and the iron sulphur protein (Xia et al., 2013). The assembly of mammalian 
complex III appears to be similar to the yeast mitochondria, and defects in five assembly 
factors have been identified to cause human diseases to date. However, the detail on 
intermediate steps of human complex III assembly is currently lacking (Fernandez-Vizarra 
and Zeviani, 2015). Complex III oxidises ubiquinol and transfers the electrons to cytochrome 
c coupled with proton pumping across the inner membrane via a Q-cycle mechanism which 
involves the generation of a semiquinone molecule (Trumpower, 1990; Xia et al., 2013). 
 
1.1.2.5 Cytochrome c 
Mammalian cytochrome c (Cytc), encoded by the CYCS gene, shuttles electrons from 
Complex III to complex IV. It is a positively charged 12.3kDA protein and located in the 
mitochondrial intermembrane space. Cytc has also been identified to play important role in 
signalling apoptotic pathway in cells (also see Section 1.1.4.1) (Liu et al., 1996; Cai et al., 
1998).  
 
1.1.2.6 Complex IV 
Complex IV (cytochrome c oxidase, COX) is the rate-limiting step of ATP synthesis as it is 
the final recipient of electrons in the OXPHOS. It comprises 13 subunits of which the three 
largest subunits (COX I-III) are encoded by the mtDNA, and the remaining subunits are 
encoded in the nucleus. The mtDNA-encoded subunits perform the catalytic function, and ten 
other subunits have the regulatory roles on oxygen consumption and proton translocation 
(Kadenbach and Huttemann, 2015). There are six isoforms subunits in mammals, which allow 
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the expression of tissue-specific functions and cell-signalling (Huttemann et al., 2012). 
NDUFA4 has been proposed as the 14th subunit of complex IV based on the 
immunoprecipitation (Balsa et al., 2012) but some researchers remain sceptical about this 
(Kadenbach and Huttemann, 2015). Currently, there are over 20 accessory proteins involve in 
complex IV assembly (Soto et al., 2012). 
Cytochrome c transfers four electrons to the haem a3-CuB binuclear centre of complex IV 
where two water molecules are formed by the reduction of an oxygen molecule, and proton 
translocation occurs (Sazanov, 2015). The rate of respiration is primarily controlled by the 
allosteric ATP-inhibition of the phosphorylated COX via feedback inhibition by ATP, 
depending on the ATP/ADP-ratio (Kadenbach and Huttemann, 2015). 
 
1.1.2.7 Complex V  
Complex V, also known as ATP synthase, comprises 15 different subunits which form two 
functional domains: F0 and F1 (Christoph von et al., 2009). F0 is located in the inner 
membrane, and it contains subunits c, a, b, d, F6, oligomycin sensitivity-conferring protein 
(OSCP) and the accessory subunits e, f, g and A6L. F1 is made up five different subunits 
(three α, three β, and one γ, δ and ε) and is located in the matrix. The two rotatory components 
are formed by the F0 subunit c (stator) and F1 subunits γ, δ and ε (rotor). The central stalk of 
ATP synthase contains F1 subunits γ, δ and ε. The peripheral stalk consists of F0 subunits b, 
d, F6 and OSCP. The rotational catalysis is accepted as the model to explain ATP synthesis 
(von Ballmoos et al., 2009). Essentially, the electrochemical proton gradient drives the 
protons from intermembrane space to matrix via F0, and the energy is transferred to F1, 
leading to the phosphorylation of ADP to become ATP (Jonckheere et al., 2012). All the 
subunits are nuclear encoded, except two F0 subunits, subunit a and subunit A6L, are encoded 
by the MTATP6 and MTAT8 genes, respectively (Jonckheere et al., 2012).The assembly of 
complex V is less well understood compared to other complexes in the OXPHOS; defects in 
three assembly factors (ATP11, ATP12 and TMEM70) have been recognised in human 
disease (Jonckheere et al., 2012). 
 
1.1.3 Reactive oxygen species 
Complex I and complex III are two major sites of reactive oxygen species (ROS) production 
in the mitochondrial electron transport chain. Complex I produce large amounts of superoxide 
(O2•−) and hydrogen peroxide (H2O2) in isolated mitochondria in two modes. First, in the 
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presence of a high NADH/NAH+ ratio in the matrix (Kudin et al., 2004); second, during 
reverse electron transport (RET) when high CoQH2/CoQ ratio and mitochondrial 
protonmotive force are evident (Δp; Δp consists of two components: the membrane potential 
(Δψ) and the pH gradient (ΔpH)). The production of O2•− by complex I during RET was at 
least 3-fold more sensitive to the pH gradient than to the membrane potential (Lambert and 
Brand, 2004). Under physiological conditions, ROS production from complex III is thought to 
be negligible when compared to complex I in vitro (Murphy, 2009).  
Excessive ROS production can lead to significant oxidative damage to mitochondrial proteins, 
membranes and DNA (Murphy, 2009). As a result, the ATP generation and various metabolic 
pathways such as the TCA cycle, fatty acid oxidation, the urea cycle, iron-sulphur biogenesis 
and others are compromised. Consequently, mitochondrial inner membrane proteins, such as 
cytochrome c, are released to the cytosol which activates caspase 3 and the cascade of 
apoptosis (see Section 1.1.4.1).  In addition, mitochondrial ROS may function as modulatable 
redox signal from the organelle to the rest of cell (Murphy, 2009). 
                                                                                                                                                                           
1.1.4 Non-OXPHOS functions 
Mitochondria have many other important functions in mammalian cells such as apoptosis, iron-
sulphur biosynthesis, calcium handling, urea cycle and others. Examples of these non-
OXPHOS functions are briefly discussed as follows. 
1.1.4.1 Intrinsic pathway of apoptosis 
Apoptosis is a tightly regulated process that causes cellular demolition and programmed cell 
death without perturbing neighbouring cells (Taylor et al., 2008). There are two major pathways 
involved in apoptosis, extrinsic and intrinsic pathways (Ichim and Tait, 2016) (Figure 4). 
Mitochondria regulate the intrinsic pathway, which can be initiated by a number of stimuli such 
as DNA damage, metabolic stress and endoplasmic reticular stress (Taylor et al., 2008). This is 
followed by an increase in the permeability of the mitochondrial outer membrane, which allows 
the release of cytochrome c to the cytosol, and formation of the apoptosome. Caspase-9 is 
activated by apoptosome, in turn, activates caspase-3 and caspase-7, leading to apoptosis. 
Mitochondrial outer membrane permeabilization is mediated by the B-cell lymphoma 2 (BCL-
2) protein family (Czabotar et al., 2014).         
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Figure 4. Extrinsic and intrinsic pathways in apoptosis. In the extrinsic apoptotic pathway, 
upon binding to their cognate ligand, death receptors such as tumour necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) receptor (TRAILR) and FAS can activate initiator 
caspases (caspase-8 and caspase-10) through dimerization mediated by adaptor proteins such 
as FAS-associated death domain protein (FADD). Active caspase-8 and caspase-10 then 
cleave and activate the effector caspase-3 and caspase-7, leading to apoptosis. The intrinsic 
(or mitochondrial) pathway of apoptosis requires mitochondrial outer membrane 
permeabilization (MOMP). Cell stresses engage BCL-2 homology domain 3 (BH3)-only 
protein activation, leading to BAX and BAK activity that triggers MOMP. Anti-apoptotic 
BCL-2 family proteins counteract this. Following MOMP, mitochondrial intermembrane 
space proteins such as second mitochondria-derived activator of caspases (SMAC) and 
cytochrome c are released into the cytosol. Cytochrome c interacts with apoptotic protease 
activating factor 1 (APAF1), triggering apoptosome assembly, which activates caspase-9. 
Active caspase-9, in turn, activates caspase-3 and caspase-7, leading to apoptosis. 
Mitochondrial release of SMAC facilitates apoptosis by blocking the caspase inhibitor X-
linked inhibitor of apoptosis protein (XIAP). Caspase-8 cleavage of the BH3-only protein 
BH3-interacting death domain agonist (BID) enables crosstalk between the extrinsic and 
intrinsic apoptotic pathways. ER, endoplasmic reticulum; MCL1, myeloid cell leukaemia 1; 
tBID, truncated BID. Reproduced with permission from (Ichim and Tait, 2016) 
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1.1.4.2 Iron-sulphur biosynthesis  
Iron-sulphur (Fe-S) clusters are inorganic cofactors that can facilitate electron transport, by 
accepting or donating single electrons. In mammalian cells, mitochondria are a major site of 
Fe-S cluster biogenesis: 12 Fe-S clusters of respiratory chain complexes I-III and those of the 
citric acid cycle enzymes aconitase and SDH (Rouault, 2015). However, it is unclear if the 
building blocks of Fe-S clusters of cytosolic proteins are dependent on mitochondria as there is 
little evidence that Fe-S clusters can cross the inner membrane to exit from mitochondria 
(Rouault, 2015). The first human disease linked to a defect in Fe-S cluster synthesis was 
Friedreich ataxia, the most common form of recessive ataxia with multi-system involvement (1 
in 50,000), caused by a homozygous guanine-adenine-adenine (GAA) trinucleotide repeat in 
the FXN gene (Koeppen, 2011). Other defects in the Fe-S biogenesis have also been identified 
to cause human disease, including myopathy, cardiomyopathy, neonatal lactic acidosis and 
sideroblastic anaemia (Rouault, 2015). 
 
1.1.4.3 Calcium handling 
It is increasingly recognised that mitochondrial calcium handling plays significant roles in 
several cellular functions, including modulating energy production, buffering cytosol calcium 
concentration under pathophysiological states and regulation of an intrinsic apoptotic pathway 
(Rizzuto et al., 2012; Williams et al., 2013). Calcium transports across the mitochondrial 
inner membrane to the matrix via a mitochondrial calcium uniporter (MCU). Genes encoding 
structural subunits of MCU have been identified, and more recently genetic defects in MCU 
have been reported to cause predominantly childhood-onset myopathy and extrapyramidal 
movement disorder (Logan et al., 2014). Altered calcium homoeostasis and mitochondrial 
dysfunction have been implicated in neuronal death and neurodegenerative disorders such as 
in Alzheimer’s disease and Huntingdon’s disease (Celsi et al., 2009). 
 
1.1.5 Mitochondrial dynamics 
An early observation of mitochondrial dynamics including variable sizes, shapes and 
networks in chick embryo (Lewis and Lewis, 1914) first provided evidence that mitochondria 
are dynamic organelles that do not conform to discrete morphology. Mitochondrial dynamic 
comprises two processes, fusion and fission, which are regulated by a number of highly 
conserved guanosine triphosphatase (GTPase) proteins as illustrated in Figure 5. 
Mitochondrial fusion is mediated by Mitofusin 1 and 2 (Mfn1 and 2) in the outer membrane 
and Optic atrophy 1 (Opa1) in the inner membrane. The main result of fusion is the formation 
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of an interconnected network which enables mitochondria to exchange content such as 
mtDNA, substrates, metabolites and lipid, which helps to maintain healthy mitochondrial 
population (Detmer and Chan, 2007). Mitochondrial fission, in contrast, creates smaller 
mitochondria which in turn facilitates mitophagy of damaged mitochondria (see 1.1.5 
Mitophagy), mitochondrial transport or accelerating cell proliferation (Archer, 2013). 
Dynamin-related protein 1 (DRP1) is one of the key proteins that promotes fission. Studies of 
human mutations in MFN2, OPA1 and PINK1 genes have further elucidated our 
understanding of mitophagy (Burte et al., 2015). Furthermore, dysfunctional mitochondrial 
dynamics has also been implicated in other neurodegenerative disorders, lung cancer and 
pulmonary arterial hypertension (Archer, 2013; Ranieri et al., 2013). 
 
 
 
Figure 5. Regulation of Mitochondrial Fusion and Fission. Mitochondrial fusion is 
mediated by homo- and heterotypic interactions between MFN1 and MFN2 (red) at the 
mitochondrial outer membrane (OM, dark green) and L-OPA1 (purple) at the inner 
mitochondrial membrane (IM, light green). MitoPLD (green) is required for OM fusion. 
Receptor-mediated recruitment of Dynamin-related protein 1 (DRP1; red) from the cytosol to 
the OM by FIS1, MFF, and MiD49/51 to sites of division marked by endoplasmic reticulum 
(ER, blue) drives mitochondrial fission. IM fission machinery is unknown. Adapted from 
(Wai and Langer, 2016) 
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1.1.6 Mitophagy 
The term ‘autophagy’ (‘self-eating’) was first coined in 1966 (De Duve and Wattiaux, 1966). 
It is a process of cellular catabolism in eukaryotic cells by which cytoplasmic materials such as 
protein and organelles are sequestered, forming double-membrane vesicles (autophagosomes) 
and are delivered to the lysosome for degradation (autolysosomes) (Yang and Klionsky, 2010; 
Youle and van der Bliek, 2012). There are two primary forms of autophagy: firstly, a non-
selective process of releasing free amino acids and other nutrients in response to starvation or 
nutrient deprivation; secondly, a more specific process involving removal of damaged or 
excessive protein and organelles (Youle and van der Bliek, 2012), such as ribosomes, 
peroxisomes and  mitochondria. Mitophagy is a degradation of mitochondria through 
autophagy that was initially observed in rat hepatocytes (Lemasters, 2005; Rodriguez-Enriquez 
et al., 2006). Mitochondria go through constant cycles of fusion and fission, with fission events 
generate two subsets of daughter mitochondria with either increased or decreased membrane 
potential. The daughter mitochondria with higher membrane potential would proceed to fusion, 
whereas the depolarised daughter mitochondria are unable to proceed to the fusion process and 
were removed by mitophagy (Twig et al., 2008). The kinase PTEN-induced putative kinase 
protein 1 (PINK1) accumulates in the damaged or depolarised mitochondria, leading to the 
recruitment E3 ubiquitin ligase parkin from the cytosol, ubiquitination of mitochondrial 
proteins and eventually the degradation of mitochondria by lysosomes (Figure 6) (Youle and 
Narendra, 2011). In addition to quality control of mitochondria, mitophagy also plays a crucial 
role in the maturation of reticulocytes (Zhang et al., 2009; Dengjel and Abeliovich, 2016). 
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Figure 6. Model of Parkin-induced mitophagy. Damaged mitochondrion (yellow) fail to 
import and degrade PINK1, leading to accumulation of PINK1 on the mitochondrial outer 
membrane. PINK1 ubiquitylates Parkin to activate the Parkin’s E3 ligase activity. Fis1 is a 
receptor on the outer membrane that binds two proteins, TBC1D15 and TBC1D17, to govern 
the developing LC3 isolation membrane to generate the autophagosome around the damaged 
mitochondria. The autophagosome is then delivered to the lysosome for degradation. 
Reproduced with permission (Pickrell and Youle, 2015) 
 
1.2 Human Mitochondrial Genetics 
1.2.1 Mitochondrial genome 
The mitochondrial genome comprises of multiple copies of mtDNA molecules. Each mtDNA 
molecule is double stranded (inner light strand (L) and outer heavy strand (H)) and has 16,569 
base pairs (bp) (Figure 7). There are 37 genes in the mitochondrial DNA, of which 24 of them 
are required for mitochondrial DNA translation (22 transfer RNAs and 2 ribosomal RNAs) and 
13 encode polypeptides that form the subunits of the mitochondrial respiratory chain namely, 7 
subunits of complex I (ND1-ND6, ND4L), 1 subunit of complex III (CYTB), 3 subunits of 
complex IV (COX I-III) and 2 subunits of ATPase (ATP6 and ATP8) (Anderson et al., 1981). 
27 of these mtDNA-encoded genes are located on the H-strand, and nine are on the L-strand 
Chapter 1: Introduction 
15 
 
(Chinnery and Hudson, 2013). The mtDNA molecule is highly compact as there are no introns 
within mtDNA genes and almost no intergenic noncoding nucleotides exist, except the 
displacement loop (D-loop), which contains transcriptional promoters and at least one of the 
proposed replication origins (OH) (Anderson et al., 1981; Tuppen et al., 2010). 
 
 
Figure 7. Human mitochondrial DNA. The outer circle represents heavy strand (H) and the 
inner circle is light strand (L). There are 37 genes in the mtDNA: 7 genes encode for complex 
I subunits (ND1-ND6, ND4L), 1 gene for complex III subunit (Cyt b), 3 genes for subunits of 
complex IV (COI-III), 2 genes for subunits of complex V (ATP7 and ATP8), 22 tRNA (denoted 
with single letter abbreviation) and 2 rRNA (RNR1 and RNR2). There are two non-coding 
regions, 1.1kb D-loop that is located in the heavy strand and the origin of L strand replication 
(OL). The origin of H-strand replication is indicated within the D-loop (OH). H-strand 
transcription is initiated either from HSP1, generating a short transcript that terminates at the 
RNR2/MTTL1 boundary (Term) under the guidance of the transcription termination factor 
MTERF, or from HSP2, generating polycistronic transcripts of the entire H-strand. LSP denotes 
the L-strand initiation point that produces polycistronic transcripts for this strand and also 
generates RNA precursors for H-strand replication initiation. Conserved sequence blocks 
(CSBs I-III) are conserved regions in human, mouse and rat that participate in the formation of 
RNA primers for replication. Transcription from all promoters requires the upstream binding 
of transcriptional activator TFAM, together with a single subunit RNA polymerase (POLRMT), 
which forms a heterodimeric complex with the transcription factor TFB2M (depicted as TFB). 
TFAM also binds to other regions of the D-loop; however, only binding to the CSB region is 
shown. Adapted from (Tuppen et al., 2010) 
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1.2.2 Unique features associated with mitochondrial DNA 
Mitochondrial genome has several distinctive features that differ from nuclear genome 
(Taylor and Turnbull, 2005): (1) maternal inheritance (Giles et al., 1980); (2) variable copy 
number of mtDNA molecules ranging from hundreds to thousands depending on the energy 
demand of the cell type; (3) heteroplasmy and threshold level; (4) bottleneck effect creating 
rapid random drift of mutation in successive generations; (5) heteroplasmy shift  in dividing 
cells due to vegetative segregation has been observed in some heteroplasmic mtDNA 
mutations such as m.3243A>G (Matthews et al., 1995; Rajasimha et al., 2008; Stewart and 
Chinnery, 2015); (6) replication of mtDNA is independent of cell cycle (Bogenhagen and 
Clayton, 1977); (7) In the mtDNA, codons AUA and AUG code for methionine, UGA codes 
for tryptophan (not a stop codon, as in the nuclear genome), and AGA and AGG are read as 
stop codons (not arginine, as in the nuclear genome) (Schon et al., 2012).  
The clinical phenotypic heterogeneity in primary mitochondrial DNA disease is partly 
explained by these unique characteristics associated with the mitochondrial genome. The 
significance of heteroplasmy, threshold effect, segregation of mtDNA mutation and 
mitochondrial genetic bottleneck in clinical practice is further discussed in Section 1.4.   
 
1.2.3 Mitochondrial DNA transcription and replication 
There are three promoters involved in the mtDNA transcription, namely HSP1, HSP2 and 
LSP (Figure 7). Transcription from both the HSP2 and LSP cover all genes, except RNR1, 
RNR2, MTTF and MTTV which are generated by HSP1 (Montoya et al., 1982; Tuppen et al., 
2010).  
The transcription begins with the interaction of mitochondrial transcription factor A (TFAM) 
with the high-affinity binding site upstream of the transcription start site followed by 
recruitment of mitochondrial RNA polymerase (POLRMT). POLRM undergoes a 
conformational change, and the mitochondrial transcription factor B2 (TFB2M) binds to it, 
forming a complex to initiate replication. Other essential components of mtDNA replicating 
machinery include polymerase ɤ, TWINKLE helicase and mitochondrial single stranded 
binding protein (mt-SSB). TWINKLE helicase is only required for the synthesis of H-strand 
DNA.  
The most well-established model to explain the replication of mitochondrial DNA is the 
strand-displacement model (SDM) (Robberson and Clayton, 1972; Berk and Clayton, 1974). 
In this model, the replication of mammalian mtDNA is thought to occur asymmetrically by 
using two separated unidirectional origins of replication, i.e. the origin of heavy (H)-strand 
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synthesis (OH) and the origin of light (L)-strand synthesis (OL). The replication initiates at the 
OH and proceeds unidirectionally, displacing the parental H-strand as a single-stranded DNA 
(ssDNA). After the two-third of H-strand is synthesised, the OL is exposed, and the 
replication of L-strand begins in the opposite direction. The replication completes after the 
two events reach a full circle (Figure 8) (Brown et al., 2005; Wanrooij and Falkenberg, 2010; 
Gustafsson et al., 2016). Bootlace model (ribonucleotide incorporation throughout the lagging 
strand, RITOLS) has recently been proposed and challenged the conventional SDM (Reyes et 
al., 2013; Holt and Jacobs, 2014).  
 
 
 
Figure 8. The strand-displacement model of mitochondrial DNA (mtDNA) 
replication. c After initiation at the heavy-strand origin (OH), the replisome (POLG (purple) 
and TWINKLE helicase (blue)) proceeds unidirectionally to produce the nascent H-strand. 
The displaced, parental H-strand is bound and stabilised by the mitochondrial single-stranded 
DNA-binding protein (mtSSB) (green). d When the H-strand replication machinery passes 
the light-strand origin (OL), a stem-loop structure is formed. The mitochondrial DNA-directed 
RNA polymerase POLRMT (orange) synthesises short primers at the stem loop, which are 
used to initiate L-strand DNA synthesis. e,fAfter completion of mtDNA strand synthesis, 
replication is terminated at either OH or OL, depending on where DNA synthesis was initiated. 
Reproduced with permission from (Gustafsson et al., 2016) 
 
Ribonuclease H1 (RNASEH1) is thought to remove the RNA part of primer in the OH region 
(from LSP to CSB2) after the initiation of mtDNA synthesis whilst the removal of the DNA 
part of the primer (from CSB2 to OH) is by the mitochondrial genome maintenance 
exonuclease-1 (MGME1) (Gustafsson et al., 2016). 
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1.2.4 Mitochondrial DNA translation 
There are four major steps in mitochondrial translation: initiation, elongation, termination and 
recycling of the ribosome (Figure 9) (Smits et al., 2010; Boczonadi and Horvath, 2014; Mai 
et al., 2016). The translational process begins with the separation of the two mitochondrial 
ribosomal subunits (small subunit/28S, mt-SSU and large subunit/39S, mt-LSU) catalysed by 
the mitochondrial translation factor mtIF3, followed by the binding of mRNA, mtIF2 and 
formylmethionine-tRNA (fMET-tRNAMet) to the peptidyl (P) site of the mitoribosome. The 
two mitochondrial ribosomal subunits then recombine and result in the release of initiation 
factors. The pairing of codon-anticodon between mRNA,  elongation factor mtEFTu, GTP 
and amino-acylated tRNA takes place at the acceptor (A) site of mitoribosome. Following the 
decoding of mRNA, the elongation factor dissociates from the mitoribosome and the amino-
acylated tRNA moves to the peptidyl (P) site of mitoribosome where the peptide bond 
formation is catalysed, adding one amino acid to the growing peptide (Smits et al., 2010). 
mtEFTs is an elongation factor that converts mtEFTu to its active form (mtEFTu-GTP) whilst 
another elongation factor, mtEFG1-GTP catalyzes the translocation step by conformational 
changes in both mtEFG1 and the mitoribosome, during which the A and P site tRNAs move 
to the P and exit (E) sites of the mitoribosome and mRNA is advanced by one codon (Smits et 
al., 2010).  This elongation step repeats itself until the stop codon (UAA, UAG, AGA or 
AGG) is encountered in the A-site (Boczonadi and Horvath, 2014). The mitochondrial release 
factor (mtRF1a) recognises the stop codon and causes the release of polypeptide attached to 
the last tRNA molecule in the P site. Other termination release factors such as mtRF1, 
C12orf65 and ICT1 are also thought to play an essential role in the termination (Boczonadi 
and Horvath, 2014).  
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Figure 9. An illustration of mitochondrial translation and protein synthesis. Following 
ribosome recycling (top), the mitochondrial small subunit (mt-SSU in blue) remains bound to 
initiation factor mtIF3 (dark green). Initiation commences as mtIF2 (light green) bound to a 
GTP molecule (red) joins this complex. Once successful recruitment of mRNA has been 
achieved and fMet-tRNAMet in the P-site anchors to the start codon, GTP is hydrolysed to 
GDP (orange), the initiation factors are released, and the mitochondrial small subunit (mt-
LSU in darker blue) can associate, forming the monosome. During elongation (centre), the 
nascent polypeptide chain is bound to a P-site tRNA, while the A-site is sampled by charged 
mt-tRNAs delivered by mitochondrial elongation factor-Tu (mtEF-Tu in yellow), until the 
correct codon-anticodon pair forms. GTP hydrolysis and mtEF-Tu release follow together 
with the exchange of the GDP (light orange) for a new GTP molecule mediated by mtEF-Ts 
(orange). The charged A-site mt-tRNA changes its conformation juxtaposing its amino acid to 
that of the extending nascent chain within the peptidyl-transferase centre. This facilitates 
peptide bond formation transferring the polypeptide chain onto the A-site mt-tRNA. The 
elongation factor mtEF-G1 (dark orange) promotes the ribosome movement that repositions 
the mt-mRNA within the 55S and the mt-tRNAs from the A- and P-sites to the P- and E-sites. 
The E-site mt-tRNA leaves the monosome in anticipation of a new round of elongation. This 
cycle continues until the polypeptide is complete and a stop codon is presented in the A-site. 
Termination (bottom) described the recognition of the stop codon by a release factor protein 
(mtRF1a in pink), which then adopts a modified conformation that promotes hydrolysis of the 
ester bond anchoring the nascent chain to the final mt-tRNA. Once the polypeptide chain is 
released, the two recycling factors, mtRRF1 (dark red) and mtRRF2 (red), promote the 
dissociation of the ribosomal subunits and premature re-association is prevented by the 
formation of a mtIF3/mt-SSU complex. Reproduced with permission from (Mai et al., 2016) 
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1.3 Prevalence of mitochondrial disease 
Mitochondrial disease was once thought rare, until two separate studies estimated the 
prevalence is approximately 1 in 5000 in the population (Skladal et al., 2003a; Schaefer et al., 
2008). Indeed, the prevalence of mitochondrial disease is comparable, if not, higher than other 
more recognisable genetic neurological disorders such as Charcot-Marie-Tooth (CMT) 
neuropathies (~1/10,000) (Foley et al., 2012; Bargiela et al., 2015),  myotonic dystrophy (3-
15/100,000) (Turner and Hilton-Jones, 2010), Huntingdon disease (1 in 10,000) (Roos, 2010) 
and limb-girdle muscular dystrophy (2.3/100,000) (Bargiela et al., 2015). 
More recently, an epidemiological study from the North East of England has further revised the 
overall prevalence of mitochondrial disease figure to 1 in 4300. This is the first attempt to 
analyse data of combined mtDNA and well-characterized nuclear gene mutations in the adult 
population (>18 years). Seventy-seven percent of adult mitochondrial disease is due to 
mutations in the mtDNA (Figure 10). The single most common genetic cause of the 
mitochondrial disease is the m.3243A>G mutation (28%). Collectively, three LHON mutations 
contribute to 29% of all cases (m.11778G>A, 16%; m.3460G>A, 11%; m.14484T>C, 2%). 
Single, large-scale mtDNA deletions which are sporadic mutations account for 12% cases. A 
rather surprising finding is recessive mutations in the SPG7 gene, encoding for paraplegin 
matrix AAA peptidase subunit, has emerged as one of the most common nuclear defects causing 
a mitochondrial disease in the adult population.   
 
Figure 10. Genetic causes of mitochondrial disease and their frequencies in the North 
East of England (n=204). Created based on (Gorman et al., 2015) 
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A study testing more than 3000 neonatal cord blood samples revealed that 1 in 200 newborns 
harbours one of the ten common mtDNA point mutations (Elliott et al., 2008). While the 
m.3243A>G mutation is the most prevalent mtDNA mutation (~1 in 400), it is worth pointing 
out that many individuals carry a very low heteroplasmy level (at least when tested in the blood) 
and likely remain asymptomatic throughout their life. This observation is supported by the 
findings of a much smaller number of patients that are clinically manifesting by two separate 
studies (4.4 in 100,000 in the North East England (Gorman et al., 2015); 18.4 in 100,000 in 
Finland (Uusimaa et al., 2007)).  
The prevalence of mitochondrial disease and frequencies of individual genotypes are clearly 
dependent on the studied populations and ethnicities (Gorman et al., 2016). For example, LS 
has been reported to be ten times more prevalent in Saguenay-Lac-St-Jean, Canada compared 
to other populations, due to a founder mutation in LRPPRC (Mootha et al., 2003); mutations in 
SUCLA2 are associated with mitochondrial depletion and LS, and the estimated prevalence of 
disease caused by a founder mutation is 1 in 2500 in Faroes Island (Carrozzo et al., 2007). The 
consanguineous marriages in some ethnicities, such as Lebanese ancestry, has been shown to 
have a much higher prevalence of recessive form mitochondrial disease compared to the general 
population (71/100,000 vs. 6.2/100,000) in Southeastern Australia (Skladal et al., 2003a; Lim 
et al., 2014). A high level of parental consanguinity has also been observed in patients of North 
African origin and complex IV deficiency (von Kleist-Retzow et al., 1998).  
The epidemiology of the paediatric mitochondrial disease is less well understood compared to 
the adult population. Mutations in mtDNA are likely only accounted for only 30% of the 
paediatric cases. Until now, genetic diagnosis has been very challenging to establish in the 
paediatric cases due to the overlapping genotype-phenotype and inherent limitations with the 
diagnostic set up such as the need for invasive biopsy and laborious candidate gene sequencing 
approach (Skladal et al., 2003b; Scaglia et al., 2004; Garcia-Cazorla et al., 2005; Debray et al., 
2007). Furthermore, another group of paediatric patients that is difficult to capture is those with 
prenatal or neonatal onset with the rapidly fatal disease, because investigations are significantly 
limited with the poor health state of these babies, and the diagnosis of mitochondrial disease is 
often only achieved at post-mortem or not at all. However, the utilisation of next generation 
sequencing technology and multi-centre collaboration is changing the speed of securing a 
genetic diagnosis for these patients. Such developments will hopefully lead to a more accurate 
estimation of the epidemiology in the paediatric population. 
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1.3.1 Mortality in mitochondrial disease 
Information on mortality data in adult mitochondrial disease is limited (Barends et al., 2016).  
The findings from several m.3243A>G mutation case series (Hammans et al., 1995; Klopstock 
et al., 1999; Majamaa-Voltti et al., 2008; Liu et al., 2012) suggest that premature deaths in 
those with significant disease burden are usually due to neurological complications (stroke-like 
episodes (SLE) and status epilepticus), cardiac involvement (cardiomyopathy and arrhythmia), 
respiratory failure due to neuromuscular weakness and precipitated by chest sepsis. The 
aetiology of death and age among those with milder phenotypes are not known. 
 
1.4 Primary mitochondrial DNA (mtDNA) mutations and disease 
Mitochondrial DNA is susceptible to mutation compared to nuclear DNA due to its close 
location to the respiratory chain that produces free oxygen radicals and lacks protective histones 
(Sastre et al., 2000). Mutations in the mtDNA can be classified into point mutations that are 
usually maternally inherited and mtDNA rearrangements (deletion and insertion) which mostly 
develop sporadically and have a low risk of transmission (Chinnery and Hudson, 2013). More 
than 300 mtDNA variants have been reported to cause human disease since 1988. Intriguingly, 
over half of these mutations are identified in tRNA genes, although tRNAs only contribute 
around 10% of the total coding capacity of the mtDNA. In contrast, 40% of the mutations are 
found in the polypeptide-encoding genes, comprising approximately 70% of the mtDNA, and 
there are very few mutations identified in two rRNA genes (Schon et al., 2012). However, many 
of these mtDNA variants (~50%) have only identified in small number of pedigrees or single 
patients, and their pathogenicity has not always been robustly validated using the gold standard 
methods (DiMauro and Schon, 2001): trans-mitochondrial cybrid studies and single muscle 
fibre study of heteroplasmic mtDNA variant (comparison of mutant heteroplasmy levels 
between COX-positive and COX-negative fibres). The challenge of determining the 
pathogenicity of novel mitochondrial tRNA variant could be addressed by applying a rigorous 
pathogenicity scoring system in the diagnostic and clinical practice (McFarland et al., 2004; 
Yarham et al., 2010). A prediction tool combining machine-learning algorithm and biological 
data (segregation, histochemistry and biochemistry) has recently been developed and might 
serve as an alternative for determining the probability of pathogenicity of a given novel mtDNA 
variant particularly when the experimental data is not available (Niroula and Vihinen, 2016).  
The majority of mitochondrial DNA disease, especially in adult patients, is caused by one of 
the following mutations: m.3243A>G, three common mutations associated with Leber 
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hereditary optic neuropathy (LHON) and large-scale, single deletion (as discussed in section 
1.3). 
 
1.4.1 Heteroplasmy, threshold level and tissue segregation 
Multiple copies of mtDNA molecule are found in cells and mutations in mtDNA usually co-
exist with the wild-type (normal) mtDNA and this is called heteroplasmy. Homoplasmy arises 
when all the mtDNA molecules are identical (either all wild-type or mutated). The expression 
of respiratory chain deficiency at the cellular level is only evident when a certain level of 
heteroplasmy is achieved, and this is described as a threshold effect. Many in-vitro studies using 
transmitochondrial cybrid cell lines (King and Attardi, 1989) have shown that many mutations 
are functionally recessive and threshold level varies considerably with a range of 60% to 90% 
(Chomyn et al., 1992; Trounce et al., 1994; Rossignol et al., 2003; Taylor and Turnbull, 2005). 
Lower tissue threshold level (70-80%) is observed in mitochondrial rearrangement (mainly 
single deletion) (Sciacco et al., 1994) compared to some tRNA mutations such as 90% in 
m.8344A>G mutation (MTTK) (Yoneda et al., 1995). Strong correlation of disease phenotype 
and tissue heteroplasmy has been observed in  some mutations such as m.8993 T>G mutation 
(MTATP6) (Santorelli et al., 1993) and more recently muscle heteroplasmy level and deletion 
size in patients with single mtDNA deletions have been used to elucidate the disease severity 
and prediction of disease progression (Grady et al., 2014) 
Ideally, the threshold level should be established by examining an individual tissue type 
directly. However, this is not always practical due to very limited access to certain tissues, for 
example, brain and other internal organs such as heart. As such, skeletal muscle is often used 
as an alternative in estimating the heteroplasmy level of other post-mitotic tissues with an 
assumption that mutation load is similarly distributed and this practice is supported by post-
mortem findings (Shoji et al., 1993; Tanno et al., 1993; Howell et al., 1994). However, clinical 
observations have revealed that the relationship of tissue heteroplasmy and clinical 
manifestation of disease is not always consistent, for example in the most common pathogenic 
mtDNA mutation, m.3243A>G (further elaboration in Section 1.4.3.1.2). 
Although threshold effect and variable segregation of mutations in different provide a 
reasonable explanation on heterogeneity in the clinical presentation of many heteroplasmic 
mtDNA mutations, they are clearly not applicable for homoplasmic mutations such as patients 
with LHON. Three common LHON mutations (m.3440A>G, m.11778A>G and m.14484T>C) 
are frequently detected in homoplasmy level (80% to 90% of the families) yet only 50% of male 
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carriers and 10% of female carriers develop visual loss at their 2nd and 3rd decade of life (Man 
et al., 2003). Several factors such as mitochondrial haplogroup, the interplay between the 
LHON mutations and the X-linked chromosome, protective effect of female sex hormone, 
environmental triggers (e.g., smoking) have been implicated (Yu-Wai-Man et al., 2014). It 
remains elusive why retinal ganglion cells are particularly susceptible to these mutations (Man 
et al., 2002) (further elaboration in Section 1.4.3.3). 
 
1.4.2 Mitochondrial DNA transmission and bottleneck effect 
The variations in mutant heteroplasmy level between generations are observed, and the degree 
of variations differs between the mutations. Such observation leads to the theory of the 
mitochondrial genetic bottleneck, which hypothesises that only a small proportion of the 
maternal mitochondrial genome is transmitted to the offspring (Stewart and Chinnery, 2015).  
Three models are currently available to provide insights on when and how the mitochondrial 
genetic bottleneck occurs. First, a bottleneck occurs at the stage of primordial germ cells 
(PGCs) due to the combination of a significant reduction in the mtDNA copy number and 
random genetic drift (Jenuth et al., 1997; Cree et al., 2008). Second, the bottleneck occurs 
during the folliculogenesis, early in the post-natal period, due to the preferential replication of 
a subgroup of mitochondrial genomes (Wai et al., 2008). Third, multiple mtDNA molecules 
are grouped into individual nucleoids, which serve as the units of segregation. The bottleneck 
occurs due to the unequal partitioning of homoplasmic segregating units within the PGCs, 
without a reduction in the mtDNA copy number in PGCs (Cao et al., 2007; Cao et al., 2009) 
(Figure 11) (Stewart and Chinnery, 2015).   
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Figure 11. Three models for the mitochondrial DNA bottleneck. PGC= primordial 
germ cell. Reproduced with permission from (Stewart and Chinnery, 2015). 
 
It is increasingly evident that size of bottleneck varies between the mtDNA mutations and a 
recent simulation study based upon a compilation of heteroplasmy levels from family 
pedigrees published in the literature and unpublished data, clearly demonstrated that the rate 
of random genetic drift varies between mutations. However, there is no evidence to support a 
‘purifying’/selective process, at least in the common point mutations such as m.3243A>G, 
m.11778G>A, m.3460G>A, m.8344A>G and m.8993T>G/C mutations that account for the 
majority of patients (Wilson et al., 2016). Tighter genetic bottleneck, such as in the case of 
m.8993T>G/C mutation, indicates a more rapid segregation of mtDNA heteroplasmy between 
generations, which explains a common scenario encountered in the clinical practice that a 
severely affected child with very high/near homoplasmic mutant heteroplasmy born to an 
asymptomatic mother who carries very low mutant load (Wilson et al., 2016). The findings of 
a variable genetic bottleneck for different mutations are also corroborated by data derived 
from the Genomes of the Netherlands (GoNL) project (Li et al., 2016).  
Selection or purifying process appears to be a plausible biological explanation on how the 
inheritable mitochondrial DNA disease is only dominated by several common mutations in 
the population, given mtDNA is so susceptible to de novo mutations. This idea is supported 
by the observation from an animal study that the severe mtDNA mutation (MTND6) was 
negatively selected against the wild type in the mouse germline and was eliminated after four 
generations, whereas the milder mutation (MTCO1) was retained in multiple generations (Fan 
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et al., 2008). However, such observation has not been replicated in the human data presented 
by a recent Dutch study (Li et al., 2016). 
  
1.4.3 Classic syndromes of mitochondrial disease 
Organs with high energy demand such as brain, skeletal muscle (including ocular muscle), 
cochlear, optic nerve, peripheral nerve, heart, and liver are particularly susceptible to 
mitochondrial dysfunction irrespective the genetic mutations (Figure 12). Neurological 
involvement by far is the most common presenting feature and majority of patients have central, 
peripheral or combined involvement, which frequently referred as mitochondrial 
encephalomyopathy (McFarland et al., 2010; DiMauro et al., 2013). The onset of clinical 
manifestation varies between different genes and often even within the group of patients sharing 
the same genetic mutation. All age groups including paediatric (antenatal period, neonatal 
onset, infancy and childhood (Goldstein et al., 2013)) and adult can be affected. 
 
Figure 12. Clinical features of mitochondrial disease. Reproduced with permission from 
(Gorman et al., 2016) 
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Historically, patients with suspected or biopsy-proven mitochondrial disease were classified 
into different clinical syndromes, primarily based on the clinical findings and occasionally, 
histopathological findings. This approach was effective in identifying groups of patients that 
were clinically homogeneous, eventually led to the findings of mitochondrial DNA mutations 
and nuclear gene mutations in several distinctive clinical syndromes such as mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic 
epilepsy with ragged red fibres (MERRF), maternally inherited diabetes and deafness (MIDD), 
Kearn-Sayre syndrome (KSS), Pearson syndrome, neuropathy, ataxia and retinitis pigmentosa 
(NARP), maternally inherited Leigh syndrome (MILS) and chronic progressive external 
ophthalmoplegia (CPEO). These syndromes are discussed individually as follows. 
 
1.4.3.1 Mitochondrial encephalomyopathy, stroke-like episodes and lactic acidosis 
1.4.3.1.1 Clinical and neuropathological characteristics 
The acronym MELAS was coined in 1984 (Pavlakis et al., 1984). Although the original case 
was presented at a paediatric neurology meeting in 1976, the full description of the original 
case of MELAS only became available 15 years later (Hirano et al., 1992). The patient was a 
girl that had a normal birth but was noted to have short stature, low birth weight and 
developed progressive muscle symptoms from age two years onwards. The first presentation 
of the stroke-like episode occurred at age 5.5 years, with documentation of loss of 
consciousness for 30 minutes, multiple episodes of dimmed vision and lactic acidosis after a 
strenuous exercise. Subsequent neurological presentations included focal sensory disturbance, 
focal and generalised seizures, with post-ictal right hemiparesis that lasted up to 3 days, 
cortical blindness and dementia. She died from heart failure at age ten years. The key 
neuropathological findings were multiple small cortical infarcts found predominantly in 
occipital and posterior temporal lobes and loss of half the neurones in the medial dorsal 
nucleus of the thalamus. In addition, capillary proliferation and hypertrophy/dilatation of 
tunica media were observed. 
The diagnostic criteria of MELAS was proposed based on the literature review of 69 cases 
(Hirano et al., 1992): (1) stroke-like episode before age 40 years; (2) encephalopathy 
characterized by seizures, dementia, or both; (3) lactic acidosis, ragged red fibres, or both; (4) 
normal early development; (5) recurrent headache; (6) recurrent vomiting. Whilst such 
diagnostic criteria improve the recognition of the clinical syndrome; there are several 
limitations. Firstly, the early case reports or case series of MELAS focused on children and 
young adults, giving an impression that stroke-like episodes only occurred below the age of 
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40. However, it is becoming clear that stroke-like episodes could develop at any age, late 
presentation of stroke-like episodes has been increasingly recognised (Minamoto et al., 1996; 
Aurangzeb et al., 2014; Marques-Matos et al., 2016). Indeed 30% of patients with MELAS 
syndrome had their first presentation of the stroke-like episode after 40 years old (unpublished 
data from Newcastle mitochondrial disease patient cohort). Secondly,  there is no specific 
clinical and radiological definition of what constitutes of a stroke-like episode and transient 
neurological symptoms associated with a migrainous headache (<24 hours) is an important 
differential diagnosis; Thirdly, dementia is a late clinical feature that often develops after 
recurrent stroke-like episodes. Furthermore, lactic acidosis and ragged red fibres are non-
specific laboratory findings of mitochondrial disease; these findings are supportive but may 
be absent in some patients with stroke-like episodes associated with the m.3243A>G mutation 
(de Vries et al., 1994), which is the most common cause of MELAS and the mutation can be 
rapidly confirmed using blood, urine or other non-invasive methods (McDonnell et al., 2004).  
Stroke-like lesions often do not confine to the vascular territories, with the predilection of 
occipital, parietal and temporal lobes involvement. These unique characteristics have been 
consistently observed in both the imaging (Majamaa et al., 1997; Stoquart-Elsankari et al., 
2008; Ito et al., 2011) and neuropathological (Gilchrist et al., 1996; Tanahashi et al., 2000; 
Sparaco et al., 2003; Betts et al., 2006) studies. The precise pathogenesis remains debatable 
(Lax et al., 2016) and the leading hypotheses are angiopathy/endothelial dysfunction 
(Hasegawa et al., 1991; Koga et al., 2005), neuronal hyperexcitability (Iizuka et al., 2002) 
and inherent OXPHOS dysfunction caused combined neuronal and vascular dysfunction 
(Gilchrist et al., 1996). The theory of angiopathy derives from the early observation of 
strongly SDH reactive vessels (the tunica media of vessel) with increase subsarcolemmal 
accumulation of mitochondria and subsequent postulation of impairment of vascular 
tone/vasodilatation leading to the development of stroke-like lesion. Findings from in vivo 
cerebral perfusion studies appear conflicting, and both under perfusion or hyperperfusion 
leading to cytotoxic/vasogenic oedema have been described (Gropen et al., 1994; Tzoulis and 
Bindoff, 2009; Ito et al., 2011). However, such variations likely represent the evolution of the 
underlying process, and stroke-like episodes are frequently under-recognized at the early 
phase. The theory of neuronal-hyper excitability advocates that the seizure increases the 
energy demand in the neurones with impaired function in the mitochondrial respiratory chain, 
leading to neuronal death and formation of a stroke-like lesion. Findings from clinical 
observation, EEG abnormalities and spreading nature of stroke-like lesions (Iizuka et al., 
2003), appear to corroborate this hypothesis.  
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1.4.3.1.2 The m.3243A>G mutation and heteroplasmy 
The most common genetic defect causing MELAS syndrome is the m.3243A>G mutation, 
accounting for 80% (n=32/40) of cases when first reported by Japanese researchers in 1992 
(Goto et al., 1992). They found that the common clinical features associated with stroke-like 
episodes were a headache with vomiting (100%), unconsciousness (85%), focal and generalised 
seizures (85%), and visual disturbance (53%). Unilateral limb weakness was only present in 
less than a quarter of patients. Lactic acidosis was almost invariably present. Abnormal 
biochemical defects were only detected in 60% of the muscle biopsies, and complex I 
deficiency (either isolated or combined) was present in 43% of cases. Strongly SDH-reactive 
blood vessels (SSVs) were identified in 88% of cases. 
The genetic defect in muscle from m.3243A>G related MELAS causes a decrease in levels of 
mtDNA-encoded polypeptides, with normal corresponding transcripts (Moraes et al., 1992). 
The threshold level for RRF formation was around 85% based on the single fibre analysis, and 
it appeared that the percentage of mutant mtDNA heteroplasmy correlated with the percentage 
of RRF. The reduction in COX activity in muscle fibres of patients with MELAS was less 
severe compared to the muscle fibres of patients with MERRF or KSS. There was no apparent 
change in the steady-state rRNA:mRNA levels, suggesting that transcription termination is not 
crucial in the pathogenesis of MELAS.  
Hammans and colleagues showed that the m.3243A>G mutation could be detected in blood, 
suggesting that a more rapid screening for the mutation was achievable without the requirement 
of muscle biopsy (Hammans et al., 1991). Subsequently, they found that the m.3243A>G was 
not detectable in 17% of patients (6/36) who were older than 37 years (Hammans et al., 1995). 
It is now well-recognized that testing the m.3243A>G mutation in blood alone could yield a 
false negative result (Rahman et al., 2001; Shanske et al., 2004). 
The spectrum of clinical features associated with the m.3243A>G mutation continued to expand 
with the detection of the mutation in patients with CPEO (Moraes et al., 1993) and MIDD 
(Guillausseau et al., 2004). The findings from cohort-based natural history studies have further 
enriched our understanding on the phenotypic heterogeneities associated with the m.3243A>G 
mutation (de Laat et al., 2012; Mancuso et al., 2013a; Nesbitt et al., 2013) and disease 
progression (Kaufmann et al., 2011). Interestingly, there is an anecdotal observation of 
intrafamilial clustering of MELAS and CPEO in the early studies (Hammans et al., 1995; 
Mariotti et al., 1995). However, this might be a selection bias and require further validation 
from prospective, large-scale studies. 
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The presence of tissue threshold and mutant mtDNA heteroplasmy in vitro has generated a lot 
of interest on studying the correlation of disease severity, phenotypes and the m.3243A>G 
heteroplasmy. An early study suggested that there was a limitation of using m.3243A>G 
heteroplasmy level in blood for genetic counselling or prognostication because of a 
considerable overlap in the level between affected individuals and asymptomatic carriers 
(Hammans et al., 1995). In contrast, a study based on the published literature showed 
statistically significant correlations between several clinical features such as stroke-like 
episodes and the m.3243A>G heteroplasmy in muscle, suggested the mutation load in muscle 
may have a prognostic value particularly among those with the level of  >90% (Chinnery et al., 
1997). However, a significant level of uncertainty remains for the majority of patients who 
harbour the intermediate level of heteroplasmy. 
 
1.4.3.2 Syndromes associated with single, large-scale deletion 
Single, large-scale mtDNA deletions were the first genetic defect in mtDNA linked to 
mitochondrial disease in humans (Holt et al., 1988). The phenotypic manifestation of single, 
large-scale mtDNA deletions ranges from severe multi-system involvement as in Pearson 
syndrome, Kearns-Sayre syndrome (KSS) to insidious chronic progressive external 
ophthalmoplegia (CPEO), of which the clinical findings are often confined to skeletal and 
ocular muscles in the latter (Pitceathly et al., 2012b).  
Kearns-Sayre syndrome was first described in the late 1950s (Kearns and Sayre, 1958) and 
the triad of clinical features are  retinitis pigmentosa, progressive external ophthalmoplegia 
with the onset below 20 years plus one or more of the following findings: heart block, 
cerebellar ataxia and raised CSF protein (> 1g/L) (Pitceathly et al., 2012b). Additional 
features may include deafness, short stature, diabetes mellitus, elevated CK, lactic acidosis 
and Fanconi syndrome (Yamashita et al., 2008).    
Pearson syndrome (PS) is characterised by exocrine pancreatic failure and sideroblastic 
anaemia that present predominantly in early childhood with an extremely poor prognosis 
(Rotig et al., 1989). Other clinical features associated with PS include renal tubulopathy and 
poor growth due to gastrointestinal dysfunction. The heteroplasmy of mtDNA deletion is 
higher in the blood than other tissues, and due to the high replication in blood cells, the 
resolution of bone marrow abnormalities has been observed in those individuals who survived 
the initial manifestation. However, the mtDNA deletion accumulates in post-mitotic tissues 
leading to the progressive nature of multi-system involvement. Some cases with the initial 
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manifestation of PS survived and evolved into clinical features compatible with KSS (Larsson 
et al., 1990) or LS (Lee et al., 2007).   
The question regarding the timing of deletion formation has prompted a lot of research 
interest.  It is intuitive to deduce that the single deletion would have occurred before the 
differentiation of three germ layers for patients who have multi-system involvement; whereas 
in patients presenting with isolated myopathy, the deletion could only occur after the 
formation of the mesoderm. An extensive study of 27 post-mortem tissues of a 59 year old 
man who had CPEO, mild ataxia, optic atrophy and cardiac involvement (Marzuki et al., 
1997) have provided some insights. The authors showed that the deletion was detectable in 
multiple tissues derived from ectodermal (CNS) and mesodermal (skeletal and ocular 
muscles) origins, with heteroplasmy levels higher in the muscle than the CNS tissues. It was 
suggested that the deletion occurred in the early embryonic development, before the 
differentiation and subsequently segregated to the ectoderm and mesoderm. After the 
identification of low levels of common mtDNA deletion 4,977 bp in human oocytes (0.1% per 
100,000 mtDNA molecule per oocyte), a study suggested that the deletion may, in fact, occur 
as early as oogenesis (Chen et al., 1995). Brenner and colleagues also showed that deletion 
was detectable in at least 1/3 of human oocytes that were studied, but more interestingly, the 
frequency of deletion was statistically significantly lower in embryos than oocytes. Whilst 
such findings have not fully supported the mtDNA bottleneck theory; these deletions might be 
eliminated by an unknown, nuclear-driven mechanism (Chen et al., 1995). A theory 
hypothesises that single deletions may, in fact, occur in grandmother’s oocyte that fertilised, 
and developed to the zygote of the mother of an affected individual. Due to the random 
genetic drift, segregation and amplification of the mtDNA with deletion, the mother’s oocyte 
that contains high heteroplasmy of mtDNA deletion is fertilised, giving birth to an offspring 
that becomes clinically affected (Chinnery et al., 2004). Based on the clinical observation, the 
risk of transmitting the deletion and causing a mitochondrial disease in an affected female is 
around 4% (95% confidence interval 1% – 12%) (Chinnery et al., 2004). Such findings lead 
to a consensus that the single, large-scale mtDNA deletions are ‘sporadic’ mutations even 
though maternally inherited single deletion has rarely been reported (Bernes et al., 1993; 
Shanske et al., 2002).  
 
1.4.3.3 Leber hereditary optic neuropathy 
LHON is characterised by acute or subacute bilateral visual loss that predominantly involves 
central vision, usually in young, otherwise healthy men (Nikoskelainen, 1984). Clinically, 
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affected patients usually present with a painless visual loss that reaches a nadir (with visual 
acuity >6/60) 4-6 weeks after the onset. Central scotoma is a characteristic visual field defect, 
and impaired colour vision is evident in the early phase, but pupillary reflexes are usually 
intact. Fundoscopic examination reveals vascular tortuosity of the central retinal vessels and 
swelling of the retinal nerve fibre layer. Of note, ~ 20% of LHON cases have a normal 
looking optic disc in the acute phase (Man et al., 2002). 
Before the identification of genetic mutation, an early, comprehensive study reported the 
median age of onset was around 20 years for males and females and spontaneous recovery of 
at least one eye was observed in ~ 45% of patients. It was observed that the risk of offspring 
developing the visual loss was higher if their mothers were affected (M:F 50% vs 24-32%) 
compared to unaffected mothers (M:F 50% vs 8%), notably the risk for female offspring was 
invariably lower than males (van Senus, 1963). The puzzle of inheritance pattern in LHON 
was not solved until the discovery of the m.11778G>A mutation in MTND4 gene in nine 
pedigrees (Wallace et al., 1988). Two other common point mutations m.3460G>A in MTND1 
(Howell et al., 1991) and m.14484T>C in MTND6 (Johns et al., 1992), together with the 
m.11778G>A, account for ~ 90% of LHON cases (Yu-Wai-Man).   
The prevailing perception about LHON is a selective involvement of retinal ganglion cell 
caused by the mitochondrial dysfunction, leading to the clinical manifestation of isolated optic 
neuropathy. Interestingly, the association of LHON and cardiac arrhythmia (frequency ~ 8-
10%) was observed in two case series (Nikoskelainen et al., 1985; Nikoskelainen et al., 1994; 
Mashima et al., 1996) (Bower et al., 1992). A study of 46 patients with LHON demonstrated 
that 59% of them have neurological abnormalities such as postural tremor (n=9), thoracic 
kyphosis (n=7), multiple sclerosis (MS) like disorder with periventricular white matter 
changes (n=2), parkinsonism with dystonia (n=1) and chronic motor tic disorder (n=1) 
(Nikoskelainen et al., 1995). Furthermore, there are patients who harbour the ‘LHON’ 
mutations and manifest with severe neurological deficits without a visual loss (McFarland et 
al., 2007). Harding and colleagues provided a compelling evidence about the link between 
LHON and multiple sclerosis by reporting a case series of eight women from different 
pedigrees who presented with classical LHON and subsequently various neurological features 
and widespread white matter lesions strongly suggestive of MS (Harding et al., 1992). In a 
blinded review of cranial MRI of three group of patients, i.e. patients with LHON (n=31), 
LHON and MS-like illness (LMS) (n=11) and MS control (n=30), the white matter changes 
seen in all LMS and a quarter of LHON (n=8) patients were deemed indistinguishable from 
typical MS (Matthews et al., 2014). The risk for female patients with LHON having 
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characteristic white matter lesions of MS was around eight times higher than males (95% CI 
2.8 – 25.1, p<0.01). 17% of LHON mutation carriers in this study had asymptomatic white 
matter changes (n=7; two females, five males). It has also been suggested that the risk of MS 
among patients with LHON is around 5% (Vanopdenbosch et al., 2000). These findings 
contradict the conclusion made by the other group that suggested the co-occurrence of LHON 
and MS was simply by chance (Pfeffer et al., 2013a).    
Incomplete penetrance and sex bias (males are at higher risk) in homoplasmic LHON 
mutations is biologically intriguing but imposes a great challenge in genetic counselling. 
Overall, for individuals who harbour homoplasmic mutations, the risk of disease is 30~50% in 
males and 5-15% in females (Man et al., 2002). Heavy smoking has been shown to be an 
independent risk factor in these individuals (Kirkman et al., 2009; Carelli et al., 2016).  
 
1.4.3.4 Myoclonic epilepsy and ragged-red fibres 
Myoclonic epilepsy and ragged-red fibres, less well known as Fukuhara disease, was first 
considered as a type of mitochondrial encephalomyopathy, manifesting with overlapping 
features of myoclonus (dyssynergia cerebellaris myoclonica, Ramsay Hunt Syndrome), 
Friedreich ataxia and myopathy with association of ragged red fibres due to mitochondrial 
dysfunction in two Japanese patients in 1980 (Fukuhara et al., 1980). The most striking 
clinical feature was childhood/teenage onset of myoclonus, accompanied by other features 
including epilepsy, mental deterioration, cerebellar ataxia, muscular atrophy and foot 
deformity. Ragged red fibres (>10%) were identified in the muscle biopsies, and the sural 
nerve biopsies showed marked fibrosis and depletion of myelinated fibres. The ragged red 
fibres were, in fact, prominent accumulations of abnormal mitochondrial especially in the 
subsarcolemmal regions when examined by electron microscopy.  
The heteroplasmic m.8344A>G mutation in MTTK gene was identified as a cause of MERRF 
in 1990 (Shoffner et al., 1990). Lipomas and hypertension appeared to be prominent features 
in addition to other neurological presentations in five generations of a large family pedigree 
(Austin et al., 1998). The age of onset, severity of symptoms and biochemical defect did not 
correlate with the mtDNA mutation in muscle (Silvestri et al., 1993). No skewed segregation 
was observed in various tissues on autopsies; no significant difference between muscle and 
blood was noted. Neuropathological findings of in another patient also had changes consistent 
with LS.  
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Cohort-based observational studies have provided a better understanding of the spectrum of 
clinical features associated with the m.8344A>G mutation over the last decade. The 
m.8344A>G mutation was present ~4% of all cases (n=42; 27 pedigrees) of mitochondrial 
disease in an Italian national cohort (~12% of all point mtDNA mutations) (Mancuso et al., 
2013b). The mean age of disease onset was 30 +/- 18 years (range 0-66; just under a third of 
patients presented under age 16 years). Features of neuromuscular dysfunction appear to be 
commoner than CNS involvement (77% vs. 56%). Muscle weakness was present in 59% of 
patients, exercise intolerance (44%), multiple lipomatosis (32%), ptosis (29%) with 
ophthalmoparesis only present in two cases (6%), muscle wasting (21%), generalized seizure 
(35%), ataxia (24%), myoclonus (24%), cardiac involvement (18%), peripheral neuropathy 
(15%) and diabetes mellitus (12%). Lactic acidemia was present in around 2/3 of cases (65%). 
The authors suggested that the origin of myoclonus might derive from the cerebellar 
dysfunction due to the association of myoclonus and ataxia (Fisher Exact test, p = 0.025), 
such association with epilepsy was lacking (p=0.176).  Uncommon clinical features (n<=2) 
were hypothyroidism, hypogonadism, dysphagia, psychiatric involvement and cataract. 
Ragged red fibres were identified in 96% of muscle biopsies (26/27), including four who were 
not myopathic. No statistical difference in the heteroplasmy (both blood and urine) level 
between carriers and affected individuals was noted. Their review of the literature (n=321) 
showed that four core features of MERRF, namely myoclonus, seizures, ataxia and ragged red 
fibres were identified in 61%, 55%, 62% and 69% of reported cases (Mancuso et al., 2013b). 
A case series with smaller numbers of patients with the m.8344AG mutation (n=15; 7 
Pedigrees) also showed muscle weakness (53%) was a commoner feature compared to 
myoclonus (40%), generalised seizure (40%) and ataxia (13%) (Catteruccia et al., 2015). Two 
third of the patients from this case series had a restrictive pattern of respiratory involvement 
and 47% of patients required ventilatory support. Cardiomyopathy and arrhythmia were 
present in 47% and 40% of the cases, respectively. EEG abnormalities (73%) were identified 
even in patients with predominant myopathic phenotype. Significant numbers of RRFs (10-
55%) were present in all but one patient. Glutei and posterior compartments of both thigh and 
leg appeared to be more affected compared to anterior compartments in five patients who 
underwent MRI muscle. Complex IV deficiency was the most severe biochemical defect 
(9/15). Mutation load in muscle was relatively homogeneous, and it did not correlate with 
clinical manifestations. The authors suggested that the variation in the frequencies of different 
clinical features in their case series might be due to the study design.  
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A case series from the German nationwide, multi-centre cohort study mitoNET (n=34; 13 
pedigrees) has recently been published (Altmann et al., 2016). More detailed clinical 
evaluation using NMDAS was performed on 16 patients. The mean age of disease onset was 
24.5 +/- 10.9 (range 6-48 years; 75% had onset 18 years or older). Deafness is the most 
common symptoms (72%), followed by cerebellar ataxia (70%), myoclonus (59%), migraine 
(52%), proximal muscle weakness (58%), muscle atrophy (39%) and others. Common 
investigations were EEG abnormalities (15/17, 88%), lactic acidemia (54%), raised CK (46%) 
and cerebral/cerebellar atrophy (43%). Muscle biopsy was performed in 8 patients, and RRFs 
were identified in 5. They found a significant association between myoclonus and seizures 
(Fisher exact test, n=23, p = 0.0128), in contrast to the Italian findings where the myoclonus 
was associated with ataxia. No correlation between heteroplasmy level and age of onset; also 
mutation level in blood did not correlate with disease severity. Interestingly, the lowest 
heteroplasmy level in an asymptomatic individual was 7% in the blood. The authors believed 
that the discrepancies in the frequency of several clinical features (e.g., hearing loss, ataxia, 
psychiatric disorder) were likely due to differences in the methods of assessment and data 
collection. 
 
 1.4.3.5 Neurogenic weakness, ataxia, retinopathy pigmentosa 
Neurogenic weakness, ataxia and retinitis pigmentosa (NARP) syndrome was first associated 
with the m.8993T>G mutation in the MTATP6 gene (Holt et al., 1990). The m.8993T>G 
heteroplasmy was detected at the level of 82% and 88% in the proband and similarly affected 
family member, respectively. The highest level (97%) was identified in the most severely 
affected individual who presented with development delay, short stature, upper motor neurone 
signs in the lower limbs, ataxia, cerebellar and brainstem atrophy (Holt et al., 1990). The 
same mutation was reported to cause Leigh syndrome (LS) in a patient who harboured high 
mutant level (>95% in multiple tissues) (Tatuch et al., 1992). The m.8993T>G mutation 
changes a conserved leucine to a positively charged arginine in the subunit a, resulting in the 
reduction of ATP synthesis (Tatuch and Robinson, 1993; Baracca et al., 2000). Furthermore, 
the correlation of mutant heteroplasmy level and ATP synthesis have also been demonstrated 
(Sgarbi et al., 2006). Generally speaking, the threshold of clinical expression of LS is thought 
to be >90%; individuals with 60-90% are less severely affected, often with NARP or are 
oligo-symptomatic (Uziel et al., 1997). However, late-onset Leigh syndrome (at age 43) has 
been reported in a Japanese patient who harboured >90% in multiple tissues (Nagashima et 
al., 1999). The m.8993T>G heteroplasmy level remains relatively constant over time, and the 
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skewed tissue segregation is uncommon. Furthermore, de novo mutations have been reported 
in at least 20% of families (White et al., 1999).    
The m.8993T>C mutation was first described in a family with Leigh syndrome (de Vries et 
al., 1993). The mutation changes a leucine to non-charge proline, causes a milder functional 
defect on the ATP synthase compared to the m.8993T>G mutation in the biochemical studies 
of fibroblasts (Vazquez-Memije et al., 1998). Childhood and adult onset NARP has also been 
observed in this mutation (Sciacco et al., 2003; Rantamaki et al., 2005). 
Homoplasmic m.9176T>C mutation can cause infantile Leigh syndrome (Dionisi-Vici et al., 
1998) and a mixed clinical picture of adult-onset progressive spastic paraparesis and axonal 
neuropathy (Verny et al., 2011). In contrast to the m.8993T>C/G mutations, the differences in 
disease onset, clinical phenotype and severity could not be explained by the mutation alone, 
the influences of mtDNA haplogroup and nuclear background have thus been suggested 
(Jonckheere et al., 2012). 
Another interesting point mutation in MTATP6 gene is the m.9185T>C mutation. Distal motor 
neuropathy and ataxia are prominent features associated with the mutation (Pfeffer et al., 
2012a; Pitceathly et al., 2012a). A study has shown that ~1% of CMT2 (distal hereditary 
motor neuropathy) is caused by this mutation (Pitceathly et al., 2012a). Progressive motor 
neurone syndrome, mimicking spinal muscular atrophy, has also been described (Brum et al., 
2014). LS has also been reported in this mutation (Childs et al., 2007). 
 
1.4.3.6 Leigh syndrome 
Leigh syndrome, also known as subacute necrotising encephalopathy, is one of the most 
common presentations of mitochondrial disease among the paediatric patients with an 
estimated prevalence of 1 in 40,000 live births (Rahman et al., 1996). Denis Archibald Leigh 
reported the first case in London in 1951. It was about a 7-month old boy who had a normal 
birth and early development for six weeks, subsequently presented with a constellation of 
neurological signs and symptoms including developmental regression, poor feeding, optic 
atrophy, and limb spasticity. A post-mortem examination revealed bilateral symmetrical 
subacute necrotic lesions in thalami, brainstem (pons and inferior olives) and the posterior 
columns of the spinal cord with relatively sparing the caudate and lentiform nuclei (Leigh, 
1951; Baertling et al., 2014). Leigh made an interesting observation that these pathological 
findings were very similar to patients with Wernicke’s encephalopathy. The core clinical 
features of LS are abnormal motor functions and intellectual retardation, usually with 
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regression, and signs of brainstem dysfunction, including respiratory failure, autonomic 
dysfunction, ophthalmoparesis/strabismus and nystagmus. Other neurological features may 
also present such as epilepsy, cerebellar syndrome and optic neuropathy (Rahman et al., 
1996). In a multi-centre retrospective study (n=130) involving a genetically heterogeneous 
group of patients (22% with mtDNA mutations of which MTATP6 was most common; 38% 
with mutations in the nuclear genes of which the common nuclear genes were SUCLA2, 
SLC19A3, SURF1 and PDHA1; genetically undetermined 40%), the median age of disease 
onset was 7 months and only 20% of patients only manifested after the age of 2 years (Sofou 
et al., 2014). The median age at death was 2.4 years (40% of the cohort, range:1 month – 21 
years).The most common presenting clinical feature was abnormal motor findings (99%) such 
as tone abnormality, muscle weakness, abnormal reflexes and extrapyramidal movement 
disorders (99%), followed by abnormal ocular findings (61%) (which include strabismus/ 
ophthalmoplegia, ptosis, nystagmus, optic atrophy and visual impairment), epilepsy (39%), 
respiratory dysfunction (38%) and mental retardation (37%). Acute exacerbation was reported 
in 57% of patients. The predictors of poor survival were the age of onset below six months, 
failure to thrive, brainstem lesions and intensive care admission.   
The definitive diagnosis of Leigh disease could only be confirmed neuropathologically (i.e., 
post-mortem) with the findings of gliosis, vacuolation, capillary proliferation with relative 
neuronal preservation predominantly affecting the brainstem and basal ganglia in the past 
(Lake et al., 2015). The advancement of or neuroimaging and genetic sequencing technology 
have revolutionised and increased the rate of premortem diagnosis (Baertling et al., 2014). 
Typical MRI head findings associated with Leigh syndrome are bilateral, symmetrical T2 
hyperintensities in the basal ganglia and brainstem (Arii and Tanabe, 2000; Baertling et al., 
2014). Lentiform nuclei appear to be most frequently identified on the MR imaging, followed 
by symmetrical signal abnormalities in the caudate nuclei and thalami in the cerebral deep 
grey matter (Sofou et al., 2013; Bonfante et al., 2016). Other less frequent imaging changes 
may include cerebellum, spinal cord and cerebral white matter. Spinal cord lesion has been 
less frequently reported on the neuroimaging of patients with Leigh syndrome, compared to 
the prominent findings in the early post-mortem studies, and this may just reflect the scanning 
practice that focuses on the brain in the clinical practice (Lake et al., 2015). Lower brainstem 
lesions (especially in the periaqueductal gray matter and reticular formation in the lower 
medulla) were frequently observed when patients lost respiratory drive (Arii and Tanabe, 
2000) and indeed a larger cohort study confirms that presence of brainstem lesion on imaging 
is one of the poor prognostic factors (Sofou et al., 2014). 
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The first mtDNA mutation that linked to LS was the m.8993T>G mutation in MTATP6 
(Tatuch et al., 1992). Intriguingly, LS appears to be more frequently caused by mutations in 
genes encoding for structural subunits such as MTATP6 and MTND1-5, compared to 
mitochondrial encoded tRNA genes in the mtDNA (Lake et al., 2016). LS caused by defects 
in nuclear gene is discussed in Section 1.5.3  
 
1.5 Nuclear genes and mitochondrial disease 
There are currently more than 200 nuclear genes linked to human mitochondrial disease 
(Koopman et al., 2012; Mayr et al., 2015) and this number continues to grow because there 
are at least 1500 mitochondrial proteins estimated by the proteomic studies (Meisinger et al., 
2008).  The nuclear-related mitochondrial disease can be classified based upon our 
understanding of the protein function, secondary defects in mtDNA and downstream 
biochemical defects in the OXPHOS (Schapira, 2012; Chinnery and Hudson, 2013). Isolated 
complex deficiencies are usually secondary to the defects in the structural subunits or 
assembly factors; in stark contrast, combined mitochondrial respiratory chain deficiencies are 
associated with multiple genes and pathways, as illustrated in Figure 13. Mutations in nuclear 
genes that are responsible for mitochondrial DNA replication and maintenance may result in 
secondary qualitative (multiple deletions) or quantitative changes (depletion, i.e., reduced 
mtDNA copy number) in mtDNA and combined respiratory chain deficiencies, for example, 
POLG, RRM2B and TWNK (aka PEO1, C10ORF2). Isolated respiratory deficiency is usually 
caused by mutations in genes encoding for OXPHOS structural subunits such as NDUFB4 
(complex I subunit) or assembly factor, for example, SURF1 (assembly factor for complex 
IV). Recessive nuclear gene mutations have a more severe phenotype with multi-organ 
involvement and paediatric onset compared to dominant mutations such as in POLG and 
RRM2B and TWNK genes, which display milder phenotype and later onset in life. However, a 
recent study reported infantile onset and severe myopathy associated with de novo mutations 
in the SUCLA4 gene, suggesting that the frequency of de no mutations may be under-
recognized in early-onset mitochondrial disorder (Thompson et al., 2016).    
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Figure 13. Nuclear gene defects causing multiple mitochondrial OXPHOS 
abnormalities. Schematic showing mitochondrial genes and pathways, many involved in key 
component steps of mitochondrial translation, in which human mitochondrial diseases 
associated with combined OXPHOS activity deficiencies have been identified. Those shown 
in red indicate disease genes identified by next-generation, largely WES studies. Reproduced 
with permission from (Lightowlers et al., 2015) 
 
1.5.1 Multiple deletions in mtDNA  
Multiple deletions in the mtDNA are an important finding of adult onset CPEO and 
mitochondrial myopathy, and the dominant inheritance was first reported back in the late 
1980s (Zeviani et al., 1989; Zeviani et al., 1990a; Zeviani et al., 1990b).  A decade later, 
single heterozygous mutations in SLC25A4 gene (encoding for adenine nucleotide translocase 
type 1, ANT1) were identified as the first nuclear gene that linked to multiple mtDNA 
deletions. ANT1 gene encodes for the heart and skeletal muscle isoform of adenine nucleotide 
translocator which is the most abundant protein in the mitochondrial matrix (Kaukonen et al., 
2000).  Subsequently, a number of nuclear genes involved in the mtDNA replication and 
maintenance have been linked to adult onset CPEO with multiple deletions in the muscle 
biopsy (Table 1) (Sommerville et al., 2014). Interestingly, a single heterozygous mutation in 
MFN2 was identified in a large family with childhood onset optic atrophy, adult onset axonal 
neuropathy and myopathy, multiple deletions in muscle biopsy but without CPEO (Rouzier et 
al., 2012). 
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1.5.2 Mitochondrial depletion syndrome 
MtDNA depletion was first recognised as a cause of mitochondrial disease in 1991 (Moraes et 
al., 1991). Moraes and colleagues identified marked COX-deficient fibres and reduction of 
the mtDNA copy number in muscle (range 3-17% of control) of two infants who presented 
with fatal encephalomyopathy and in the liver (range 12% of control) of an infant that died 
from liver failure. Tissue-specific expression of mtDNA depletion was noted.   
Mitochondrial depletion syndrome (MDS) has since emerged as an important group of 
mitochondrial disorder and is clinically and genetically heterogeneous.  Broadly speaking, 
there are four clinical phenotypes associated with mtDNA depletion, which includes 
hepatocerebral syndrome, encephalomyopathy, pure myopathy and neurogastrointestinal 
involvement (Nogueira et al., 2014). The underlying molecular mechanisms are related to 
either a defect in the mtDNA replication (POLG and TWNK) or mitochondrial 
deoxynucleotide (dNTP) pool regulation (TK2, DGUOK, RRM2B and TYMP) (Suomalainen 
and Isohanni, 2010). Succinyl-CoA ligase is an enzyme involved in the Kreb cycle and 
mutations in the alpha subunit (SUCLG1) and beta subunit (SUCLA2) cause mtDNA 
depletion, although the precise mechanism is unclear. Similarly, the function of MPV17 is not 
completely characterised. More recently, POLG2 (Varma et al., 2016)and TFAM (Stiles et al., 
2016) mutations have been associated with infantile-onset liver failure and added to the 
expanding list of gene in MDS. The clinical features of these genes associated with MDS are 
summarised in Table 1.  
Recessive mutations in the TWNK cause infantile onset spinocerebellar ataxia (Nikali et al., 
2005) and hepatocerebral syndrome (Hakonen et al. 2007). The refractory nature of epilepsia 
partialis continua, hypotonia and liver dysfunction in those cases described to have infantile 
onset spinocerebellar ataxia, in fact, are reminiscent of Alpers syndrome caused by POLG 
mutations (Hakonen et al., 2007). A systematic review of POLG mutations associated with 
epilepsy is discussed in Section 3.2. 
For the CNS involvement, common features of MDS are hypotonia, dystonia, seizure and 
encephalopathy. However, Leigh or Leigh-like disease appears to be very uncommon in MDS 
(Suomalainen and Isohanni, 2010), except in SUCLA2 (Carrozzo et al., 2007; Ostergaard et 
al., 2007) and SUCLG1. Given we know about the primary function of Succinyl-CoA 
synthase in Krebs cycle, the precise mechanism of SUCLA2 causing mtDNA depletion is not 
known. Cardiac manifestation is rare in most of the maintenance genes except in a case series 
that showed 14% of patients with mutations in SUCLG1 developed hypertrophic 
cardiomyopathy (Carrozzo et al., 2016). 
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Gene Protein MtDNA 
depletion 
Clinical presentation/ tissue specificity Other features related to 
MDS  
MtDNA multiple 
deletions  
CPEO 
 CNS Liver Muscle GI  
DGUOK Deoxyguanosine 
kinase 
+ Dystonia, nystagmus + +  Hypoglycaemia Not reported  N/A 
MPV17 MPV17 + Demyelination in CNS 
& PNS 
+   Navajo neurohepatopathy, 
neuropathy, hypoglycaemia  
Not reported N/A 
TWNK Mitochondrial Twinkle 
helicase 
+ Alpers-like; IOSCA +   Valproate toxicity, athetoid 
movement 
Yes + (ad) 
POLG Catalytic subunit of 
polymerase gamma 
+ Alpers syndrome +  + Valproate toxicity; 5% with 
MNGIE-like feature 
Yes + (ad, ar) and 
other clinical 
phenotypes* 
POLG2 Accessory subunits of 
polymerase gamma 
+  +    Yes + (ad) 
RRM2B p53-R2 + Hypotonia  + Rare Neuropathy, renal 
tubulopathy, MNGIE-like 
Yes + (ad) 
SUCLA2 Beta subunit of 
succinyl-CoA ligase 
+ LS, dystonia  +  Deafness; methylmalonic 
aciduria; prevalent in Faroes 
Island 
Not reported N/A 
SUCLG1 Alpha subunit of 
succinyl-CoA ligase 
+ LS, dystonia    Deafness; methylmalonic 
aciduria; cardiomyopathy 
(14%)  
Not reported N/A 
TK2 Thymidine kinase 2 + Seizure              
(uncommon) 
Uncommon Rapidly 
progressive 
myopathy 
 Raised CK level, SMA-like 
phenotype, type II 
respiratory failure 
Yes + 
TFAM Mitochondrial 
transcription factor A 
+  +   Hypoglycaemia, IUGR Not reported N/A 
TYMP Thymidine 
phosphorylase 
+ Encephalopathy   + MNGIE syndrome, 
demyelinating neuropathy, 
high thymidine in blood, 
low TP enzyme activity  
Yes + (ar) and MNGIE 
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DNA2 DNA replication 
helicase 2 
Not 
reported 
N/A N/A N/A  N/A Yes + (ad); Seckel 
syndrome (ar) 
MGME1 Mitochondrial genome 
maintenance 
exonuclease 1 
+ Mental retardation, 
spinal deformities 
 +  Respiratory failure (NIV), 
low BMI, renal colics 
Yes + (ar) 
RNASEH1 Ribonuclease H1 Not 
reported 
N/A N/A N/A  N/A Yes + (ad) 
SPG7 Paraplegin Not 
reported 
N/A N/A N/A  N/A Yes + (ad, ar) with 
spastic ataxia 
AFG3L2 Subunit of m-AAA 
proteases 
Not 
reported 
N/A N/A N/A  N/A Yes + (ad), SPG28 
FBXL4 F-box/LRR-repeat 
protein 4 
+ Hypotonia, seizure   + Dysmorphic features, RTA,  Not reported N/A 
 
Table 1. Mutations in the mtDNA maintenance nuclear genes associated with mitochondrial depletion syndrome and/or multiple deletions. 
BG= basal ganglia, CK= creatinine kinase, CNS= central nervous system, CPEO= chronic progressive external ophthalmoplegia, GI = gastrointestinal 
system, IUGR= intrauterine growth restriction, IOSCA= infantile onset spinocerebellar ataxia, LS= Leigh syndrome, MDS= mitochondrial depletion 
syndrome, MNGIE= mitochondrial neurogastrointestinal encephalopathy, N/A= not applicable, PNS= peripheral nervous system, RTA= renal tubular 
acidosis, SMA= spinomuscular atrophy, SPG28= spinocerebellar ataxia type 28, (ad) = autosomal dominant, (ar)= autosomal recessive, *= Other 
clinical phenotypes associated with mutations in POLG include myoclonic epilepsy myopathy sensory ataxia (MEMSA)/ spinocerebellar ataxia with 
epilepsy (SCAE) and ataxia neuropathy syndrome/ sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO)/ mitochondrial recessive 
ataxia syndrome (MIRAS)      
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1.5.3 Leigh syndrome 
Pyruvate dehydrogenase deficiency secondary to mutations in the PDHA1 gene on the X 
chromosome was the first nuclear gene mutation associated with LS (Matthews et al., 1993). 
Overall, the complex I deficiency was thought to be the cause of Leigh syndrome in at least 
one-third of patients (Rahman et al., 1996). This is unsurprising given that complex I is the 
largest enzymatic complex of OXPHOS, with 45 subunits and increasing number of assembly 
factors implicated in the biosynthesis of the complex (Zhu et al., 2016). Isolated complex IV 
deficiency is the next common biochemical defect associated with LS (Gerards et al., 2016). 
Complex II and III deficiencies infrequently result in the development of LS. Currently, the 
most frequently reported genetic causes (with >50 cases reported in the literature) are SURF1 
(Wedatilake et al., 2013), PDHA1-related pyruvate dehydrogenase deficiency (Patel et al., 
2012), LRPPRC (which frequently regarded as French-Canadian Leigh disease) (Debray et 
al., 2011), followed by NDUFS4, NDUFS1, NDUFV1 (>20 cases reported in the literature) 
(Lake et al., 2016; Ortigoza-Escobar et al., 2016), SUCLA2 (estimated homozygote frequency 
of 1 in 2500 in the population of Faroes Island) (Carrozzo et al., 2007) and MTFMT (~20 
cases) (Tucker et al., 2011; Neeve et al., 2013; Haack et al., 2014). To date, over 75 genes 
have been shown to cause LS (Lake et al., 2016). However, there remains a significant 
proportion of patients (>50%) that are genetically undiagnosed (Wortmann et al., 2015).  
 
1.6 Making a diagnosis of mitochondrial disease 
1.6.1 Roles of neuroimaging 
Imaging of brain and spinal cord is a useful diagnostic tool when investigating suspected 
cases of mitochondrial disease. Symmetrical calcification in basal ganglia is a common 
abnormality identified on CT head, but it is a non-specific finding and can be seen in other 
conditions such as hypoparathyroidism (Sachs et al., 1982) and Fahr’s disease (Wang et al., 
2012). MRI head is a preferred radiological modality and often helps to characterise CNS 
involvement and evolution of the underlying pathological process in mitochondrial disease 
(Saneto et al., 2008) (Figure 14). For example, symmetrical, striatal T2/FLAIR 
hyperintensities are radiological hallmarks of Leigh syndrome and additional signal 
abnormalities in the brainstem may be identified in these patients when presenting with acute 
crisis and cranial nerve palsies. Acute stroke-like lesions associated with MELAS typically 
show restricted diffusion with mixed ADC map changes (i.e., mixed cytotoxic and vasogenic 
oedema) in parietal, temporal and occipital lobes; these lesions may resolve over time. 
Extensive white matter changes have been recognised in patients with KSS, and these changes 
Chapter 1: Introduction 
 
44 
 
may be associated with cerebral folate deficiency (Allen et al., 1983; Serrano et al., 2010). 
Delayed myelination may be present in paediatric patients that manifest with developmental 
delay and hypotonia. Progressive radiological features of neurodegeneration irrespective of 
genotype are often evident on serial brain imaging (Valanne et al., 1998; Barragán-Campos et 
al., 2005; Scaglia et al., 2005; Tschampa et al., 2013; Bindu et al., 2015).  
 
Figure 14. Radiological findings associated with mitochondrial disease. (A) CT head 
shows bilateral calcification in basal ganglia. (B) Axial T2-weighted MRI head shows 
symmetrical signal abnormalities in bilateral globus pallidi, typically seen in Leigh syndrome. 
(C) Axial T2-weighted MRI shows hyperintensities in the medulla in a young adult who 
presented with acute Leigh crisis. (D) FLAIR sequence of MRI head shows acute stroke-like 
lesions in the right temporal and occipital lobes of a patient who harbours the m.3243A>G 
mutation, corresponding with changes of restricted diffusion seen on DWI sequence (E). (F) 
Axial T2 weighted MRI shows diffuse white matter signal abnormalities identified in an 
adolescent with single, large-scale mtDNA deletion and Kearns-Sayre syndrome. 
 
Interestingly, characteristics radiological changes have been observed in mitochondrial 
disease caused by mutations in several mitochondrial tRNA synthetases, which may help 
direct genetic testing. Leukoencephalopathy with brainstem and spinal cord involvement and 
high lactate (LBSL) is caused by mutations in DARS2 (Steenweg et al., 2011) whilst 
leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL) has 
been observed in EARS2 mutations (Steenweg et al., 2012). On the other hand, 
pontocerebellar hypoplasia type 6 has been linked to RARS2 mutations (Edvardson et al., 
2007). However, clinical phenotypes associated with these genetic mutations are expanding, 
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and cases with additional imaging findings (Biancheri et al., 2015) or lacking typical imaging 
abnormalities (Nishri et al., 2016) previously described are increasingly being reported. 
 
1.6.2 Current diagnostic approach 
As discussed in the previous sections, making a diagnosis of mitochondrial disease remains 
formidable due to the genotypic and phenotypic heterogeneity. It requires a collaborative 
effort from clinicians and scientists from different disciplines namely histopathology, 
biochemistry, molecular genetics and increasingly bioinformatics. Comprehensive diagnostic 
criteria and algorithms of investigating mitochondrial disease have been published by the field 
experts to provide a framework for clinicians (Bernier et al., 2002; Taylor et al., 2004; Taylor 
and Turnbull, 2005; McFarland et al., 2010; Parikh et al., 2015; Gorman et al., 2016) (Figure 
15). Classic syndromes such as MERRF, MELAS and LHON can be diagnosed by testing 
common mtDNA point mutations in blood or urine. However, it is important that clinicians 
are cognizant of the fact that the m.3243A>G heteroplasmy level declines in blood with age, 
probably due to a negative selection against the mutant mtDNA (Rahman et al., 2001; 
Frederiksen et al., 2006) and such a diagnostic caveat is clearly outlined by a study that 
showed the m.3243A>G mutation was not detectable in blood, but present in the urine 
samples of 13% of their subjects (Shanske et al., 2002).  
Many mitochondrial diseases do not have pathognomonic features that point towards a 
particular genetic diagnosis and biopsy of the affected tissue, most commonly skeletal muscle 
is advocated as a gold standard investigation. Routine light microscopy study of the muscle 
biopsy may identify RRFs, best appreciated with modified Trichomori stain, as a non-specific 
finding frequently associated with mitochondrial disease; though RRF is often absent in 
paediatric cases (Koenig, 2008; Gerards et al., 2016). COX-deficient fibres can be better 
demonstrated by using sequential COX/SDH histochemistry (Figure 16). More recently, a 
novel quadruple immunofluorescent technique with high reproducibility and sensitivity has 
been developed in Newcastle. This sensitive assay allows an objective measurement of key 
structural subunits of complex I and IV, and has a potential to be translated into the diagnostic 
setting (Rocha et al., 2015). Measurement of respiratory chain complex activities and 
ubiquinone (Coenzyme Q10) quantifies the extent of complex deficiencies (isolated or 
combined deficiency, ubiquinone deficiency) and helps to target candidate genes employing 
Sanger sequencing technique. Other methods of molecular genetics include real-time PCR 
(quantitative measurement of mtDNA copy number), long-range PCR (to detect mtDNA 
rearrangement- single, large-scale deletion or multiple deletions), pyrosequencing 
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(quantifying heteroplasmy level) and sequencing of whole mtDNA (to detect rare or novel 
point mutations in mtDNA).  
Currently, the diagnostic process is laborious and time-consuming after primary mtDNA 
mutations have been excluded. This is especially true in cases of combined respiratory chain 
deficiencies as highlighted in that the diagnostic yield of individual nuclear gene sequencing 
can be less than 5% (Kemp et al., 2011).   
 
.   
 
Figure 15. Current pathway of investigating mitochondrial disease in the UK. 
Reproduced with permission from (McFarland et al., 2010) 
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Figure 16. Common histopathological abnormalities in muscle biopsies observed in 
mitochondrial disease. The sections highlight two fibres stained or reacted for the following: 
(A) haematoxylin and eosin (H&E) staining to show general muscle morphology, in this case 
identifying abnormal, granular fibres showing basophilic rims; (B) modified Gomori 
trichrome stain highlighting these as classical ragged-red muscle fibres; (C) COX 
histochemistry showing that these fibres are COX-deficient to differing degrees; (D) the SDH 
reaction which reveals the subsarcolemmal accumulation of mitochondrial activity is 
exclusively found in mitochondria; (E) sequential COX/SDH histochemistry highlighting 
COX-deficient fibres, which retain SDH activity. Adapted from (Greaves et al., 2012) 
 
1.6.2.1 Predictive genetic testing for the mtDNA mutations 
Pre-test genetic counselling for currently asymptomatic maternal family members regarding 
the primary mitochondrial DNA disease is challenging due to the marked variability regarding 
the threshold effect of individual mutations, disease onset, clinical manifestation, disease 
progression and prognosis frequently observed within families. The implications of predictive 
genetic testing are outlined as follows: 
(1) Surveillance for complications associated with the underlying mtDNA mutations 
Cardiac involvement is common in many mtDNA mutations (Bates et al., 2012) 
and is associated with increased morbidity and mortality (Malfatti et al., 2013; 
Mancuso et al., 2013b; Catteruccia et al., 2015; Wahbi et al., 2015). Left 
ventricular hypertrophy is the most common type of cardiac abnormality and, 
though often subclinical, may progress to decompensated heart failure in some 
individuals. Moreover, sudden cardiac death in the m.3243A>G mutation has also 
been reported (Majamaa-Voltti et al., 2008; Kaufmann et al., 2011). Predictive 
genetic testing should, therefore, be offered to at-risk maternal family members so 
that they receive regular cardiac surveillance and treatment. In addition, 
anticipatory guidance for pre-symptomatic individuals and health care personnel 
can be provided on recognising severe neurological complications such as stroke-
like episodes, seizures and brainstem dysfunction that are frequently associated 
with certain mtDNA defects such as mutations in MTTL1 and MTND5. 
Recognising other systematic involvement such as diabetes mellitus, renal 
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involvement and sensorineural deafness can be associated with  mtDNA mutations 
could avoid unnecessary diagnostic work up. On the other hand, a negative genetic 
result would provide reassurance and avoid unnecessary medical follow up. 
 
(2) Modification of environmental risk factors 
Smoking has been established to significantly increase the risk of developing optic 
neuropathy among individuals affected by LHON (Kirkman et al., 2009; Carelli et 
al., 2016) and therefore advice on lifestyle modification is imperative for those 
asymptomatic family members. 
 
(3) Family planning and reproductive options 
The estimated prevalence of primary mtDNA disease derived from the most recent 
cohort based study is approximately 1 in 5000 (Gorman et al., 2015). A 
population-based study showed that the prevalence of m.3243A>G mutation was 
over 1 in 400 (236 per 100,000) (Manwaring et al., 2007), suggesting there is an 
under-diagnosis of a significant number of individuals especially those who are 
oligosymptomatic (Gorman et al., 2016). It is also likely that some people may 
remain asymptomatic throughout their life due to low mutant heteroplasmy levels. 
However, female carriers, irrespective of their clinical state, are still at risk of 
transmitting the mtDNA mutation to their offspring who may be severely affected 
due to the unpredictable nature of mtDNA genetic bottleneck. Currently, 
reproductive options such as PGD and mitochondrial replacement therapy (aka 
mitochondrial donation) shortly (Herbert and Turnbull, 2017) offer the opportunity 
for reducing the risk of transmitting the mtDNA mutations to the offspring. 
Similar to the Mendelian genetic disorders, presymptomatic and predictive genetic testing for 
the mtDNA mutations in the paediatric population is contentious because of its ethical 
implications such as removal of the child’s autonomy on deciding for genetic testing 
especially mutations are associated with adult onset disease, and risk of stigmatisation 
(Valente et al., 2008). Therefore, such testing should be limited to those mutations with a high 
risk of childhood onset complications after discussing with parents and highlighting the 
caveat that mutant heteroplasmy level cannot solely explain the variability of clinical 
phenotypes and potential disease burden in the future. 
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1.6.3 Novel biomarkers 
1.6.3.1 Human fibroblast growth factor 21 
Human fibroblast growth factor 21 (FGF21) is one of the 22 proteins that belongs to the FGF 
superfamily. It is expressed in the metabolically active organs which include liver, pancreas, 
white adipose tissue, thymus, and skeletal muscles (Long and Kharitonenkov, 2011). FGF21 
plays important roles in glucose and fatty acid metabolism during the fasting and fed states. 
Peroxisome proliferator-activated receptor alpha (PPAR-ɑ) induces the expression of FGF21 
in hepatocytes as well as circulating level in response to fasting, resulting in hepatic fatty acid 
oxidation, ketogenesis and gluconeogenesis (Long and Kharitonenkov, 2011; Woo et al., 
2013). FGF21 can increase glucose uptake in adipocytes, increase insulin secretion and inhibit 
glucagon release in the pancreas, inhibit lipolysis and hence decrease free fatty acids (Woo et 
al., 2013).The elevation of FGF21 level has been associated with several common diseases 
such as obesity, diabetes mellitus, ischaemic heart disease, non-alcoholic fatty liver disease, 
polycystic ovarian syndrome, chronic renal failure and diabetic nephropathy, and 
Cushing’syndrome (Woo et al., 2013; Fisher and Maratos-Flier, 2016) and post-exercise in 
healthy subjects (Kim et al., 2013). 
The observation of increased FGF21 level in the mitochondrial myopathy was first reported in 
mitochondrial helicase TWINKLE mouse model with dominant mutation (Tyynismaa et al., 
2010). Suomalainen and co-workers proposed that FGF21 is a potentially helpful diagnostic 
biomarker in mitochondrial disease after investigating a cohort of 67 patients with 
mitochondrial disorders caused by different genetic mutations (22 adults and 12 children, 94% 
with genetic diagnosis), 34 disease controls (mixture of genetic muscle diseases and acquired 
neuromuscular disorders such as inclusion body myositis and motor neuron disease) and 74 
healthy controls. They found that the sensitivity and specificity were close to 92% in adult 
and child muscle-manifesting mitochondrial disorders (Suomalainen et al., 2011). Similar 
diagnostic sensitivity (91% with 95% CI 86-97%) in the adult patients (n=54, mean age 51, 
range 20-70) has also been replicated by the Australian researchers and them also identified 
that the level of elevation was higher among those who had proximal myopathy, compared to 
those who without muscle weakness in the disease group and control (Davis et al., 2013). 
More recently, elevated FGF21 has been identified in myotonic dystrophy type 1, similar to 
patients with mitochondrial disease. Insulin resistance appears to be a plausible mechanism to 
explain such elevation (Lovadi et al., 2016). 
The diagnostic potential of FGF21 in the paediatric setting remains unknown. In general, 
children with mitochondrial disease are more frequently manifest CNS disease and less so 
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with myopathy when compared to the adult patients. The use of FGF21 in paediatric patients 
might be limited because the sensitivity of FGF21 in diagnosing adult patients with 
mitochondrial disease primarily manifesting with CNS dysfunction was merely 42% 
(Suomalainen et al., 2011).  
The FGF21 level appeared to correlate with disease burden (measured with the NMDAS) in 
patients harbouring the m.3243A>G mutation. However, its role in monitoring disease 
progression was thought to be limited (Koene et al., 2014).  
 
1.6.3.2 Growth differentiation factor 15 
Growth differentiation factor 15 (GDF-15) belongs to the transforming growth factor beta 
superfamily, and it is ubiquitously expressed. The biological function of GDF-15 is not well 
characterized but it has been studied as biomarker or predictor of adverse outcome in several 
conditions, including chronic liver disease (Lee et al., 2016), acute kidney injury (Heringlake 
et al., 2016), white matter hyperintensities in cognitive impairment (Chai et al., 2016) and 
chronic heart failure (Lok et al., 2013). GDF-15 was first proposed as a potential biomarker in 
mitochondrial disease following a transcriptomic study of skeletal muscle from patients with 
TK2 mutations (Kalko et al., 2014). Overall, the serum GDF-15 concentration was elevated 2 
to 11 folds in both paediatric and adult patients with the mitochondrial disease compared to 
the healthy and disease controls, as demonstrated by different studies (Yatsuga et al., 2015; 
Davis et al., 2016; Montero et al., 2016). The sensitivity of GDF-15 varies between studies: 
the lowest being 68% (Montero et al., 2016), the intermediate is 79% (Davis et al., 2016) 
whilst the highest has been reported to be 98% (Yatsuga et al., 2015). The much greater 
sensitivity reported by the Japanese group (Yatsuga et al., 2015) is probably related to all the 
patients have confirmed genetic diagnosis with classic syndromes compared to the other two 
studies. The specificities, on the other hand, are very similar in these studies (>90%). The area 
under the curve (AUC) value using ROC curve analysis for GDF-15 has also been shown to 
be consistently higher than FGF-21 as well as other conventional biomarkers (e.g., lactate, 
CK level), suggesting its superiority as a diagnostic biomarker. Furthermore, the elevation of 
the GDF-15 level is not restricted by myopathic phenotype (Yatsuga et al., 2015; Montero et 
al., 2016), compared to FGF-21 (Suomalainen et al., 2011).  
However, there might be a potential limitation of GDF-15 when evaluating suspected cases 
with single organ involvement such as cardiomyopathy at the outset of presentation, because 
patients with isolated heart failure (disease control) had a comparable elevated GDF-15 level 
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compared to the mitochondrial disease group (Yatsuga et al., 2015). Furthermore, the 
negative predictive value was reported to be only 61% in a study (Montero et al., 2016), 
indicating that the exclusion of mitochondrial disease could not be based on this biomarker 
alone in day-to-day clinical practice. 
 
1.6.4 Next generation sequencing 
Next generation sequencing (NGS) is a new and high-throughput technique that allows 
sequencing of multiple candidate genes is simultaneously leading to a more rapid diagnosis 
and increase the diagnostic yield (Tucker et al., 2010). The diagnostic yield of whole exome 
sequencing (WES) in mitochondrial disease has been reported to range from 17% and up to 
55% (Table 2). New genes linked to mitochondrial respiratory chain defects are constantly 
identified via WES, with clinical phenotypes overlapping with other known genes. On the 
other hand, the spectrum of clinical phenotypes of known genes is also expanded with such 
unbiased diagnostic approach. One of the biggest challenges with the NGS is to provide proof 
of pathogenicity for novel variants in the known genes, and perhaps more so for the new 
genes that have not been previously linked to any disease. Segregation study of affected and 
unaffected family members would help to prioritise the analysis of variants of unknown 
significance (VUS). Detailed understanding of clinical phenotypes and identification of other 
affected individuals from different pedigrees are the pivotal step of validating the diagnosis 
(Calvo et al., 2012). Multi-centre collaboration is often required to identify these patients 
because many of these VUS are rare. In the circumstance of private mutations which 
segregation study cannot be performed, further in vitro studies such as Western blotting, 
mutant cell characterization, rescue experiment and animal modelling are required (Legati et 
al., 2016).  
Biopsies of affected tissues and biochemical measurement of these samples are invaluable 
when interpreting the WES findings, and they would continue to have a major role in the 
diagnostic work up in mitochondrial disease for the foreseeable future. However, it is also 
increasingly recognized that a number of genetics or ‘acquired’ neuromuscular diseases could 
have secondary histopathological, biochemical, ultrastructural changes similar to the primary 
mitochondrial disorders (Joshi et al., 2014; Pyle et al., 2015; Rygiel et al., 2016; Vincent et 
al., 2016), again highlighting the complexity of investigating patients with evidence of 
‘mitochondrial dysfunction’ in some cases.    
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Study N Inclusion criteria Overall diagnosis Candidate genes Non-mito genetics 
Calvo et al. 2012 42 Infants with clinical features 
and biochemical defects  
23 (55%); 10 were 
known variants 
13 (31%; pathogenicity 
proven in two genes) 
N/A 
Haack et al. 
2012Δ 
10 CI deficiency, onset age<3 yo 7 (70%); 2 patients had 
MTFMT mutations 
N/A N/A 
Lieber et al. 2013 102 Clinical and biochemical 
defined with variable onset 
age 
New diagnosis 8 (out of 
84) and 17 (out of 18) 
previously diagnosed 
cases*  
26 (25%; pathogenicity 
proven in the ATP5A1 
gene) 
3 (3%) 
DPYD (CI, CIII 
deficiencies), KARS, WFS1 
(multiple deletions) 
Ohtake et al. 2013 104 Neonatal and infantile-onset 
mitochondrial respiratory 
chain deficiencies 
18 (17%) 27 (26%) N/A 
Taylor et al. 
2014Δ 
53 Combined respiratory chain 
deficiencies; age of onset: at 
birth – 17yo 
28 (53%) 4 (8%) N/A 
Wortman et al. 
2015Δ 
109 Clinical scoring and 
biochemical defects (muscle 
biopsy, n=94; fibroblast, 
n=92) 
42 (39%): 
  HS - 24/42 
  IS  - 10/44 
  LS – 8/23 
 Half of the diagnosis were 
non-mito genes (21;19%) 
Khoda et al. 2016 142 Respiratory chain 
deficiencies, onset age <15yo 
49 (39%); 3 novel genes 
with proven 
pathogenicity (MRPS23, 
QRSL1, PNPLA4) 
 7 (5%); MECP2 (CI 
deficiency), TNNI3 (CI 
deficiency) and pathogenic 
chromosomal deletions 
Legati et al. 
2016Δ 
125 Clinical and biochemical, 
onset age: 78<1yo, the rest 
with mean age 18.6yo 
15 (12%) and 6 (out of 
10) had undergone WES 
27 (22%) 4 (CYP2U1, PREPL, E4F1, 
RANBP2) 
Table 2 Summary of reported clinical studies applying gene panels and WES (n=8). Δ= primary mtDNA mutations and single, large-scale 
deletions were excluded prior to the WES. *= the m.3243A>G mutation was not detected by the WES in a known case with 3% m.3243A>G 
heteroplasmy in blood. CI= complex I, CIII= complex III, N/A= not applicable, HS= high suspicion of mitochondrial disease, IS= intermediate 
suspicion of mitochondrial disease, LS= low suspicion of mitochondrial disease  
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1.7 Current management of mitochondrial disease 
Patients with mitochondrial disease often develop multi-system involvement. Active 
surveillance and regular follow up are crucial to identifying specific deficits which may not be 
apparent at the outset of initial clinical manifestation. Although there remains no cure for 
mitochondrial disease, there is an organ-specific supportive measurement that may offer 
alleviation of symptoms, reduction of disease burden and potentially life-saving treatment. 
Specific treatments are available for several forms of mitochondrial disorders (Parikh et al., 
2009; Parikh et al., 2015; Gorman et al., 2016). 
 
1.7.1 Supportive treatment  
1.7.1.1 Acute neurological crises 
The most severe, acute neurological complications in mitochondrial disease are 
decompensation of brainstem function frequently associated with LS and status epilepticus 
associated with or without stroke-like episodes. These events often are triggered by 
intercurrent illnesses such as infection and dehydration. Prompt recognition of acute 
brainstem dysfunction such as new onset cranial nerve palsies, altered breathing pattern or 
hypersomnolence is crucial to circumvent delay in treatment in the high dependency or 
intensive care unit. For stroke-like episodes, the mainstay of treatment remains aggressive 
seizure management whilst optimising nutritional support and treating the potential 
underlying triggers. L-arginine, a precursor of nitric oxide, has been advocated to treat 
metabolic stroke based on positive findings from anecdotal case reports (Koga et al., 2002; 
Kubota et al., 2004; Shigemi et al., 2011) and a single open-labelled trial (Koga et al., 2005; 
Koenig et al., 2016). However, there might be a research bias because of the nature of open-
labelled trial design. Further clinical trials are currently underway, and more conclusive 
results are awaited. An open-labelled trial showed that citrulline could mitigate baseline lactic 
acidosis in patients with MELAS (El-Hattab et al., 2014). However, its effect on acute stroke-
like episodes has not yet been demonstrated.  
 
1.7.1.2 Chronic neurological problems 
Input from a specialist physiotherapist and an occupational therapist is vital to managing 
chronic neurological complications such as tone abnormalities, myopathy and ataxia in 
patients affected by mitochondrial disease (McFarland et al., 2010). In addition, 
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pharmacological treatments such as benzodiazepine, baclofen and Botulinum toxin injections 
may be beneficial for patients with dystonia and spasticity. Parkinsonism is common in 
certain genotypes such as mutations in POLG (Luoma et al., 2004; Orsucci et al., 2011) and 
dopamine agonists/replacement therapy may be considered as symptomatic therapy.  
 
1.7.1.3 Hearing loss 
Progressing hearing deficit with preferential involvement of high-frequency hearing loss is a 
common manifestation seen in many patients with mitochondrial disease. The underlying 
pathology has been localised to cochlear dysfunction (Chinnery et al., 2000; Kullar et al., 
2016). Hearing aids could improve mild to moderate deafness whilst placement of a cochlear 
implant is an option for those with severe hearing loss (Rosenthal et al., 1999; Santarelli et 
al., 2015; Yamamoto et al., 2015). 
 
1.7.1.4 Ocular disease 
Ptosis is a common finding in patients with CPEO. Corrective measures such as frontalis sling 
and ptosis props may improve both vision and cosmetic appearances significantly. However, 
caution should be exercised in those with facial weakness because of complications associated 
with over-correction (McFarland et al., 2010).  
But perhaps most promising, has been the licensing of the use of idebenone in patients with 
LHON by the European Medicine Agency (EMA) (further discussion in Section 1.8.2.2). 
 
1.7.1.5 Malnutrition and gastrointestinal dysfunction 
Malnutrition is commonly observed in patients with moderate to severe mitochondrial disease 
burden. This may be secondary to dysphagia due to bulbar/pseudo-bulbar dysfunction, 
myopathy or loss of appetite, or early satiety secondary to the underlying gut dysmotility. 
Swallowing and nutritional assessment should be considered early so that appropriate dietary 
advice may be given to minimise the risk of aspiration and optimisation of nutrition. For those 
with an unsafe swallow and significant weight loss, gastrostomy feeding may be a solution. 
Total parenteral nutrition (TPN) may be temporarily used in patients who have intestinal 
pseudo-obstruction (IPO), and occasionally prolonged use might be necessary due to a 
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protracted period of severe gut dysmotility. Monitoring for liver dysfunction is important, but 
particularly in the chronic use of TPN (Wang et al., 2015).  
 
1.7.1.6 Cardiac and respiratory management and surveillance 
Cardiac involvement is evident in 30% of adult patients with mitochondrial disease (Wahbi et 
al., 2015). Genotype-specific cardiac complications have been observed, for example, 
hypertrophic cardiomyopathy (HCM) and Wolf-Parkinson-White syndrome (WPW) in 
m.3243A>G and m.8344A>G-related mitochondrial disease; bradyarrhythmia including heart 
block in single, large-scale deletion (Bates et al., 2012); Sengers syndrome, characterized by 
cardiomyopathy and congenital cataracts, caused by mutations in AGK (Haghighi et al., 
2014). Early recognition provides a window opportunity to initiate pharmacological agents 
that can modulate cardiac remodelling and preserve cardiac function, ablation therapy for 
accessory pathways in WPW syndrome and insertion of a pacemaker could be life-saving in 
those who develop complete heart block (Bates et al., 2012).  
Advanced respiratory insufficiency necessitating non-invasive ventilation secondary to 
neuromuscular weakness is considered relatively uncommon in mitochondrial disease (Pfeffer 
et al., 2015), except in patients with KSS due to single, large-scale deletion, m.8344A>G 
(Catteruccia et al., 2015), and mutations in TK2 (Alston et al., 2013). A more detailed study 
of 26 patients with CPEO (mixed genotypes) showed mild respiratory muscle weakness was 
evident, particularly in patients with limb-girdle weakness although forced vital capacity was 
within normal range (Smits et al., 2011).  
 
1.7.1.7 Solid organ transplant 
Several genotypes manifest with tissue-specific involvement and may progress to end-stage 
organ failure. The role of solid organ transplantation is increasingly recognised as a 
therapeutic strategy in mitochondrial disease. Hepatic failure is a common feature associated 
with mitochondrial depletion syndromes such as mutations in DGUOK and MPV17; liver 
transplantation has been performed in these cases, with improved clinical outcome associated 
with milder neurological involvement (Dimmock et al., 2008; Uusimaa et al., 2014). 
Decompensated cardiomyopathy has been shown to benefit from heart transplantation in 
ACAD9 (Collet et al., 2016) and m.3243A>G-related mitochondrial disorders (Bhati et al., 
2005). Successful kidney transplantation has also been reported in patients with both 
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m.3243A>G (Jansen et al., 1997; Lederer et al., 2010) and single, large-scale mtDNA 
deletions (Rötig et al., 1995). A recent retrospective study of 35 patients from 17 centres 
clearly demonstrated liver, kidney and cardiac transplants were well-tolerated by patients with 
mitochondrial disease (mixed genotypes) with improved survival, except in patients with 
mutations in POLG (Parikh et al., 2016). However, better survival following liver 
transplantation in cases of POLG mutations has been reported in another study (Hynynen et 
al., 2014).  
 
1.7.2 Vitamin and cofactor supplements 
Vitamin and cofactor supplements, either in isolation or combination (cocktail), are 
commonly used in patients with various forms of mitochondrial disease (Parikh et al., 2009). 
While there is no robust evidence for many of these supplements (Pfeffer et al., 2012b), 
significant benefits have been observed in subgroups of patients. For example, riboflavin 
(Vitamin B2) is beneficial in patients with multiple acyl-CoA dehydrogenase (MADD) 
deficiency caused by mutations in ETFDH (Olsen et al., 2007; Zhu et al., 2014) and 
SLC25A32 (encoding for mitochondrial flavin adenine dinucleotide transporter) (Schiff et al., 
2016), as well as mutations in ACAD9 (encoding for flavin adenine dinucleotide-containing 
flavoprotein) (Gerards et al., 2011).  
 
1.7.3 Exercise therapy 
Aerobic training (Taivassalo et al., 1998) (Jeppesen et al., 2006; Taivassalo et al., 2006; Bates 
et al., 2013) has been shown to be safe and efficacious at improving exercise capacity as well 
as the quality of life in mitochondrial myopathies. However, there is no change in 
mitochondrial respiratory chain function, mutant heteroplasmy level, mtDNA copy number 
and muscle fibre morphology (Jeppesen et al., 2006; Taivassalo et al., 2006). Resistance 
training has also been shown to be of benefit in patients with single, large-scale deletion 
through the activation of satellite cells and regeneration of myofibres (mitochondrial 
biogenesis) (Murphy et al., 2008). 
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1.7.4 Targeted treatments for specific conditions 
1.7.4.1 Mitochondrial neurogastrointestinal encephalomyopathy 
MNGIE is caused by a deficiency of thymidine phosphorylase, encoded by TYMP gene 
(Nishino et al., 1999). The main therapeutic aim is to restore enzymatic activity and decrease 
the levels of plasma thymidine and deoxyuridine. Two approaches have been attempted with 
clinical and biochemical improvements observed: erythrocyte-encapsulated thymidine 
phosphorylase (n=1) (Bax et al., 2013) and allogeneic haematopoietic stem cell 
transplantation (AHSCT). However, there is a significant safety concern regarding AHSCT 
because of its associated high morbidity and mortality (Halter et al., 2015). Liver 
transplantation (n=1) has recently been proposed to be a new, attractive alternative to AHSCT 
(De Giorgio et al., 2016).  
 
1.7.4.2 Primary CoQ10 deficiency 
Primary CoQ10 deficiency is associated with five major phenotypes: severe, infantile 
multisystem disease, encephalomyopathy, nephrotic syndrome, cerebellar ataxia and isolated 
myopathy (Emmanuele et al., 2012). Supplementation of high dose CoQ10 has ameliorated 
symptoms and disease progression in some patients (Pineda et al., 2010; Emmanuele et al., 
2012). 
 
1.7.4.3 Ethylmalonic encephalopathy 
Ethylmalonic encephalopathy is characterised by early onset encephalopathy, 
microangiopathy, haemorrhagic diarrhoea, accumulation of sulphide (H2S) and COX 
deficiency due to mutations in the ETHE1 gene, which encodes for mitochondrial matrix 
sulphur dehydrogenase (Haack et al., 2012 3441). Supplementation of combined N-acetyl 
cysteine and metronidazole appears to be an effective treatment for patients with ethylmalonic 
encephalopathy (Viscomi et al., 2010). 
 
1.7.5 Prevention of transmission 
Genetic counselling on the risk of disease transmission is a major focus in clinical 
management. Mitochondrial disease caused by defects in nuclear gene follows the rules of 
Mendelian inheritance, and their risk assessment is relatively straightforward. In contrast, the 
risk prediction of primary mitochondrial DNA mutations is complicated due to the 
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mitochondrial genetics bottleneck (Section 1.4.2). Even for homoplasmic mtDNA mutations, 
it remains very difficult to quantify the risk of disease due to incomplete penetrance and 
environmental factors (Gorman et al., 2016) (Section 1.4.3.3).  
Prenatal testing for nuclear gene disorders is well established and currently includes 
preimplantation genetic testing (PGD), chronic villous sampling (CVS) and amniocentesis. 
CVS and amniocentesis are associated with a risk of miscarriage. Prenatal testing of primary 
mtDNA mutations was first introduced into the UK in 2007 (Nesbitt et al., 2014). PGD is 
now also offered to women with mtDNA mutations. It involves in vitro fertilisation (IVF), 
and biopsy of developing embryos (at the one or two blastomeres stage) with high-quality 
embryos with the lowest mutant mtDNA heteroplasmy levels implanted, and if successful, 
results in pregnancy (Richardson et al., 2015; Gorman et al., 2016). One of the most 
challenging aspects of PGD in mtDNA mutations is to determine the threshold level of 
clinical expression for the individual mutation (Hellebrekers et al., 2012; Sallevelt et al., 
2013). Moreover, PGD is not an effective option for patients with homoplasmic mtDNA 
mutations (Lightowlers et al., 2015; Richardson et al., 2015).  
 
1.8 Emerging, potential therapeutic strategies  
There are a number of major developments in creating animal models and finding novel 
therapies for different types of mitochondrial disease over the last decade (Rai et al., 2015). 
Currently, the research of potential therapeutic strategies could be divided into two broad 
categories (Figure 17): first, targeted therapy aimed at the underlying genetic defect; second, 
generic treatment targeting improving mitochondrial function irrespective of the genetic 
mutations. The first approach could be highly efficacious and potentially leads to a cure 
although their application is genotype-specific and may be very costly to develop. On the 
other hand, although generic treatment is not curative, it may be more cost-effective and could 
potentially benefit more patients and have wider applications in other neurodegenerative 
disorders. 
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Figure 17. Emerging, potential therapeutic options for patients with mitochondrial 
disease. AICAR= 5-Aminoimidazole-4-carboxamide ribotide, dNTP= deoxynucleotide pool, 
ETHE1= mutations in this gene cause ethylmalonic encephalopathy, mt-aaRs= mitochondrial 
amino-acyl tRNA synthetases, ROS= reactive oxygen species TYMP= mutations in this gene 
cause MNGIE, TALEN= transcription activator-like effector nucleases, ZFN= zinc finger 
nuclease. Adapted from (Lightowlers et al., 2015; Rai et al., 2015) 
 
1.8.1 Targeted treatment 
1.8.1.1 Mitochondrial donation 
Mitochondrial donation is emerging as a promising strategy to prevent transmission of 
primary mtDNA disease, especially for those women with very high heteroplasmic or 
homoplasmic mutations. It is an IVF technique and requires healthy donor eggs. The transfer 
of a patient’s nuclear genome can be performed on the fertilised oocyte (pronuclear transfer) 
or before the egg is fertilised (spindle transfer) (Figure 18) (Richardson et al., 2015). New 
regulations to allow mitochondrial donation was debated and approved in the UK in February 
2015, after more than ten years of extensive preparations including public consultation and 
several independent scientific and ethical reviews (Kmietowicz, 2015). A recent study 
provides further preclinical evidence on the safety profile of pronuclear transfer and its 
potential for reducing the risk of manifesting with the disease. However, offspring born to this 
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technique may still harbour mtDNA mutations. Therefore, the prevention of mutant mtDNA 
carryover is not guaranteed (Hyslop et al., 2016). 
 
Figure 18. Mitochondrial donation. (A): Pronuclear transfer: MII-arrested oocytes obtained 
from the affected woman and a healthy donor are fertilized and the pronuclei are transferred 
in a karyoplast from the affected woman's fertilised egg to the enucleated donor 
egg. (B): Spindle transfer: oocytes obtained from an affected woman and a healthy donor are 
enucleated by removal of the MII spindle and its chromosomes in a karyoplast. The 
karyoplast from the affected woman is fused with the enucleated oocyte from the healthy 
donor. Reconstituted oocytes are then fertilised and undergo the second meiotic division 
followed by formation of the male and female pronuclei. Abbreviations: MII, second meiotic 
division; PN, pronuclei. Reproduced from (Richardson et al., 2015). 
 
1.8.1.2 Manipulation of mutant mtDNA heteroplasmy 
Zinc fingers nucleases (ZFN) (Gammage et al., 2014) and transcription activator-like effector 
nucleases (TALEN) (Bacman et al., 2013) have been used experimentally to manipulate the 
ratio of mutant and wild-type mtDNA in cell lines and have shown an impressive reduction of 
mutant heteroplasmy level below the phenotypic expression threshold. Furthermore, use of 
MitoTALEN has been attempted in the mouse germ line and provided proof of concept of its 
potential efficacy in preventing mtDNA transmission (Reddy et al., 2015). However, neither 
technique would be applicable to homoplasmic mtDNA mutations; nor substantial reduction 
in the mtDNA copy number in cell lines with subsequent recovery raises a severe concern of 
safety in vivo (Nightingale et al., 2016). 
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1.8.1.3 Gene therapy 
Another form of targeted approach is gene therapy based on adeno-associated virus vector 
(AAV). For example, delivery of AAV-ETHE1 to the liver of a mouse model has restored 
enzymatic activity and improved survival (Di Meo et al., 2012), which may be translated as 
an effective treatment for patients with ethylmalonic encephalopathy. Allotropic expression of 
synthetic ND4 gene for the m.11778G>A mutation (which is the most common cause of 
LHON) appears to be a promising treatment from the in vitro studies (Ellouze et al., 2008). 
Currently, a randomized, double-blind, sham-controlled clinical trial is recruiting patients 
with visual loss associated with the m.11778G>A mutation to evaluate the effectiveness of 
gene therapy (ClinicalTrials.gov identifier: NCT02652767) 
 
1.8.1.4 Supplementation of deoxyribonucleotide 
Supplementation of deoxyribonucleotide or inhibition of its catabolism has been shown to 
increase mtDNA copy number and mitochondrial respiratory function in cell lines with either 
deoxyguanosine kinase (mutations in DGUOK) or thymidine phosphorylase (mutations in 
TYMP) deficiency (Camara et al., 2014). Moreover, supplementation of deoxycytidine and 
deoxythymidine monophosphates (dCMP and dTMP) in TK2 knockout mice has shown 
positive phenotypic and biochemical improvement (Garone et al., 2014). 
 
1.8.2 Generic treatment 
1.8.2.1 Increase mitochondrial biogenesis 
Mitochondrial biogenesis refers to an increase in the copy number of mitochondria in cells. It 
is regulated by the peroxisome proliferator-activated receptor gamma coactivator (PGC1-α), 
which is frequently known as the key regulator of cellular metabolism and mitochondrial 
biogenesis because of its interactions with multiple transcription factors (Liang and Ward, 
2006). Stimulation of mitochondrial biogenesis is an attractive treatment strategy that may 
improve underlying mitochondrial dysfunction and therefore potentially ameliorate clinical 
symptoms. Several existing drugs that are licenced for other treatment purposes have been 
shown to modulate PGC1-α via different pathways. Bezafibrate is an agonist for the 
peroxisome proliferator-activated receptor (PPAR) and has been primarily used as a lipid-
lowering agent. Currently, there is phase II clinical trial investigating the efficacy of 
bezafibrate in mitochondrial myopathy (m.3243A>G mutation) (ClinicalTrials.gov identifier: 
NCT02398201) in Newcastle. Resveratrol is another mitochondrial proliferator that increases 
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NAD+ (oxidised nicotinamide adenine dinucleotide) which subsequently activates PGC1-α 
(Nightingale et al., 2016); in an open-labelled trial, high dose Resveratrol appeared to 
improve the clinical rating scale. However, no improvement was observed in cardiac function 
or patient-reported outcome neurological function in patients with Friedreich ataxia (Yiu et 
al., 2015). Another agent, 5- Aminoimidazole -4-carboxamide ribonucleotide (AICAR) was 
initially designed as a cardiac-protective drug, and has been shown to increase mitochondrial 
biogenesis by activating the AMP-activated protein kinase (AMPK).  
Mammalian target of rapamycin (mTOR) is a kinase that involves in mitochondrial oxidative 
through a YY1-PGC-1alpha transcriptional complex (Cunningham et al., 2007). Rapamycin, 
an mTOR inhibitor, has been experimented in a mouse model of LS (NDUFS4 knockout 
mouse) and demonstrated significant improvements in neurological function and survival 
(Johnson et al., 2013). This is rather intriguing because mTOR is important for mitochondrial 
biogenesis and the downstream effects of inhibiting mTOR are not yet well characterized. It 
has been postulated that the rescue of phenotype might be related to the metabolic shift 
towards amino acid catabolism and away from glycolysis. However, the side effects such as 
immunosuppression and growth restriction may preclude its clinical use, particularly in the 
paediatric population. 
Maintaining the ratio of NAD+ and NADH is important in oxidative phosphorylation. 
Supplementation of NAD+ with nicotinamide riboside (Vitamin B3) has shown increased 
mitochondrial biogenesis in two mouse models (Cerutti et al., 2014; Khan et al., 2014). The 
mechanism has been attributed to the activation of sirtuins SIRT1 and SIRT3 (Lightowlers et 
al., 2015). Acipimox, another NAD+ precursor, holds potentials in the treatment of 
mitochondrial myopathy, as shown by a recent study were it boosts mitochondrial function in 
the skeletal muscle of patients with type II diabetes mellitus (van de Weijer et al., 2015). 
 
1.8.2.2 Antioxidant 
Accumulation of ROS could deplete the pool of antioxidants such as glutathione in cells 
which further compromises mitochondrial and cellular functions (Rahman, 2015). Many past 
and present therapeutic studies have focused on finding anti-oxidants that could ameliorate 
the damaging effects of ROS. Co-enzyme Q10 (CoQ10) is the most widely used supplement 
in clinical practice due to its theoretical benefit of improving electron transfer in the 
mitochondrial respiratory chain and its anti-oxidative effect. Benefits of supplementing 
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CoQ10 in patients with primary ubiquinone deficiency have been observed (Section 1.7.4.2). 
However, the wider application of CoQ10 in mitochondrial myopathy has not yielded any 
positive results in several clinical trials (Pfeffer et al., 2012b).  
Idebenone is a potent, synthetic CoQ10 analogue and has been trialled in patients with 
LHON. The primary end point for the LHON trial did not reach statistical significance, but 
post-trial ad hoc analysis suggests its use may benefit patients with discordant visual acuities 
(i.e. those who are at high risk of losing sight in the other eye) (Klopstock et al., 2011).  
EPI-743 is a synthetic analogue of Vitamin E, which is an anti-oxidant and in vitro studies 
have shown that it has a potency that is a thousand fold higher than CoQ10 and idebenone. 
Two open-label trials of EPI-743, with a small number of paediatric patients with mixed 
phenotypes and genotypes, have shown some clinical improvement (Enns et al., 2012; 
Martinelli et al., 2012). A randomised, controlled trial of EPI-743 in Leigh syndrome has 
since been completed but the formal report of trial primary and secondary outcomes is still 
awaited (ClinicalTrials.gov identifier: NCT01721733).  
Other novel, small molecular therapies with an anti-oxidative activity that are currently tested 
in clinical trials including RP103 cysteamine bipartite (ClinicalTrials.gov identifier: 
NCT02023866) and KH176 (Koopman et al., 2010) (ClinicalTrials.gov identifier: 
NCT02909400). 
 
1.9 Natural history and cohort studies in mitochondrial disease 
Improvement in the diagnostic strategies with the application of NGS has solved the 
diagnostic conundrum of many cases of mitochondrial disease. Furthermore, our 
understanding of the biochemical defects and molecular mechanisms of mitochondrial disease 
has benefited greatly from in vitro studies of patient cell lines and animal models over the last 
two decades. However, risk stratification and surveillance for complications, prediction of 
disease progression and prognostication are extremely challenging in the clinical setting. The 
limitation in the longitudinal and natural history data creates significant barriers to developing 
medical management guidance, determining the timing for therapeutic trial and outcome 
measures, which are patient-centred and clinically relevant. The m.3243A>G mutation is a 
great example to illustrate these points. It is well-known to cause MELAS syndrome, which 
manifests as recurrent SLEs, yet the clear natural history of these SLEs such as clinical and 
radiological evolution, the interval between the SLEs and extent of recovery following each 
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SLE is largely lacking, and only reported in small case series or single cases. On the other 
hand, only ~20% of m.3243A>G mutation carriers develop MELAS syndrome yet currently 
there is no predictive tool to provide accurate prognostication for other maternal family 
members especially those who are currently asymptomatic. Phenotypic heterogeneities are 
often also observed even within the same family pedigrees: CPEO, renal disease, MIDD, 
exercise intolerance and cardiomyopathy, to name a few examples. These factors have to be 
considered when devising surveillance programme for complications, inclusion criteria of 
clinical trial and outcome measures. More stringent patient selection would limit the patient 
recruitment from a single source, and multi-centre collaboration would be imperative to 
achieve sufficient sample size especially for randomized-controlled trials (Pfeffer et al., 
2013b). 
 
1.9.1 The MRC Mitochondrial Disease Patient Cohort 
The clinical and diagnostic service for mitochondrial disease is centralised to three centres in 
the UK: Newcastle upon Tyne, London and Oxford. Mitochondrial Disease Patient Cohort 
(MitoCohort), is a collaborative project initiated by these three centres and funded by the 
Medical Research Council (MRC) since 2009. Two main objectives of MitoCohort are: first, 
to improve our understanding of natural histories of mitochondrial disease caused by different 
genetic mutations based on prospective and longitudinal observation; second, to promote trial 
readiness of a large group of well-characterized patients. The current recruitment criteria are: 
1) individual should be alive when enrolled to the cohort; 2) biochemical evidence or genetic 
confirmation of mitochondrial disease; 3) asymptomatic carriers of genetic mutation are 
included. There is no restriction on age.  
Newcastle is the largest national centre and is actively followed up 57% of patients (~800) 
recruited to the MitoCohort (Figure 19). Patients are comprehensively assessed using 
Newcastle Mitochondrial Disease Adult Scale (NMDAS), a validated clinical assessment tool 
(Schaefer et al., 2006) specific to adult patients with mitochondrial disease. A baseline 
NMDAS is performed at the patient’s first visit and repeated on subsequent follow-up, 
typically every 12-24 months. Results of past and present clinical investigations such as 
routine blood tests, ECG, echocardiography, brain imaging, neurophysiological studies 
(electroencephalogram, nerve conduction studies and electromyography) and muscle biopsy 
findings are also collected systematically on the MitoCohort database. 
Chapter 1: Introduction 
65 
 
 
 
 
Figure 19. The MRC Mitochondrial Disease Patient Cohort. (A) Heat map constructed 
based on patients’ post codes. Patients with mitochondrial disease are actively recruited in the 
North East England, where Newcastle is situated. (B) Pie chart shows a total number of 
patients and percentage of patient recruited by the individual centre (updated on 28th October 
2016). (C) The layout of cohort database.
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2.1 Aims and scope 
The main aims of this thesis were: (1) to delineate the clinical and genetic spectrum of 
mitochondrial DNA and nuclear gene disorders in the Mitochondrial Disease Patient Cohort, 
Newcastle; (2) to identify potential prognostic factors that may aid risk stratification, 
surveillance and conception of treatment guidelines that may be implemented into clinical 
practice (Figure 20).  
 
Figure 20. Utilisation of the MRC Mitochondrial Disease Patient Cohort and translation 
of research findings into clinical practice. 
 
2.2 Overview of Mitochondrial Disease and Neurological Presentations 
In the invited review (co-authored with Professor Doug Turnbull), I briefly discussed the 
genetics and epidemiology of mitochondrial disease and emphasised the crucial step of 
diagnosing mitochondrial disease is still dependent on meticulous clinical assessment and 
interpretation of family history. I highlighted the acute and chronic clinical presentations of 
mitochondrial disease that ‘jobbing’ neurologists may encounter in the clinical setting and 
gave an overview of the current evidence for specific and supportive treatments, surveillance 
for complications, genetic counselling and reproductive options.  
Recessive POLG mutations remain one of the most common nuclear gene-related forms of 
mitochondrial disease seen in both paediatric and adult populations. In a systematic review 
(joint first author with Maria-Eleni Anagnostou), I performed a comprehensive literature 
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search and analysis of all POLG related epilepsy cases published to date (n=372) and detailed 
the associated spectrum of clinical, electrophysiological and radiological features, 
neuropathological findings and molecular genetics. I determined that there is a bimodal 
distribution of age of disease onset with females presenting later than males. Seizures, 
especially in cases of epilepsia partialis continua, were often refractory to multiple 
pharmacological agents in vast majority of cases. I confirmed that the clinical outcome of 
POLG-related epilepsy was influenced, in part, by the location of pathogenic variants in the 
gene and presence of hepatic dysfunction. These findings provide greater insight into disease 
trajectory and prognosis and highlight the need for an improved or alternative treatment 
strategy.    
 
2.3 Interrogating the clinical manifestations of m.3243A>G-related mitochondrial 
disease 
The m.3243A>G mutation is the most common pathogenic mutation in adult patients, 
manifesting with marked heterogeneity in clinical manifestations, between individuals and 
within pedigrees; as well as between different tissues. Cardiac involvement, in the form of 
hypertrophic cardiomyopathy or Wolff-Parkinson-White syndrome, is recognised clinical 
entities associated with this mutation. However, following two unrelated cases of sudden 
adult death syndrome (SADS), I interrogated their clinical and autopsy findings and reviewed 
the cause of death in other family pedigrees. Initially, the most striking finding was that both 
individuals were asymptomatic carriers of the m.3243A>G mutation with high mtDNA 
heteroplasmy. Review of other family pedigrees led to the identification of six other SADS 
cases. Such findings affirmed the importance of cardiac surveillance even among the 
‘apparently’ asymptomatic mutation carriers. My findings helped devise a prediction tool to 
identify patients who are at risk of developing cardiac complications of m.3243A>G-related 
disease. Development of this risk stratification tool has facilitated more extensive surveillance 
on high-risk patients, as advised in the manuscript and has led to a revision of the Newcastle 
best practice cardiac guidelines.  
While I was analysing the cardiac involvement in patients with the m.3243A>G mutation, I 
noted that severe gut dysmotility, manifesting as intestinal pseudo-obstruction (IPO) was 
often recorded. I also observed a few patients required emergency hospital admission for 
treatment.  Intestinal pseudo-obstruction (IPO) is a typical feature associated with MNGIE 
caused by mutations in the TYMP gene, however, it has only been reported in case reports or 
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small, retrospective case series of patients with the m.3243A>G mutation. I sought to study 
the clinical features and radiological characteristics of severe IPO (mimicking an acute 
surgical abdomen) in patients harbouring the m.3243A>G mutation, to document the clinical 
outcome especially among those who underwent surgical interventions, and to determine its 
prevalence. I identified risk factors for the development of severe IPO in patients with 
m.3243A>G and these findings have informed the derivation of gastrointestinal screening and 
management guidelines for adult patients (these guidelines are available at 
http://www.newcastle-mitochondria.com/clinical-professional-home-page/clinical-
publications/clinical-guidelines/). 
    
2.4 Investigating The Spectrum of Extrapyramidal Movement Disorders in 
Mitochondrial Disease  
Descriptions of extrapyramidal features associated with mitochondrial disease are often based 
on individual genetic mutations. In addition, there are limited data on the treatment options of 
extrapyramidal movement disorders and their efficacy in mitochondrial disease. I aimed to 
determine the frequency and spectrum of extrapyramidal movement disorders seen in children 
and adults and review their response to conventional treatments. My findings suggest that the 
genotype-phenotype correlates in this study may provide guidance on targeting genetic 
screening. I observed that reduction in dopaminergic uptake on nuclear imaging did not 
appear to predict treatment response to dopaminergic drugs in the adult patients (data on 
paediatric patients were too limited to make any meaningful conclusions). Further research of 
extrapyramidal movement disorders in mitochondria disease is warranted, given the 
debilitating nature of these symptoms and limited understanding of their pathogenesis.  
 
2.5 Characterising Nuclear Genes in - Combined mitochondrial respiratory chain 
deficiencies 
Combined mitochondrial respiratory chain deficiencies are associated with heterogeneous 
groups of genetic mutations and clinical phenotypes. Mutations in the RMND1 (Required for 
Meiotic Nuclear Division protein 1) gene were initially identified as a cause of multiple 
respiratory chain defects in infantile encephalomyopathy using WES. Subsequently, milder 
cases with sensorineural deafness and renal disease were also reported. In a multi-centre 
collaboration project, I sought to define the clinical, biochemical and molecular genetic 
spectrum associated with the mutations in RMND1 gene. I performed survival analysis to 
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identify possible favourable factors associated with better clinical outcome. I also highlighted 
the importance of screening for renal complications, given it was identified in two-third of 
patients. The recognition of renal involvement is important, as there are effective supportive 
treatment strategies such as anti-hypertensive medication and correction of electrolyte 
imbalance, and potentially life-saving management such as kidney transplant. 
Intriguing clinical manifestations with unusual combinations of organ involvement have been 
reported in defects of mitochondrial amino-acyl tRNA synthetases. The YARS2 gene encodes 
for mitochondrial tyrosyl-tRNA synthetase and mutations in this gene have been linked to 
myopathy, lactic acidosis and sideroblastic anaemia (MLASA) syndrome particularly in 
individuals of Middle-Eastern ancestry. I identified six cases from four unrelated family 
pedigrees (three Scottish families). The first two pedigrees were identified via WES, and 
direct YARS2 gene sequencing was performed on two families based on the interpretation of 
clinical phenotypes. A final genetic diagnosis was provided (with the supporting evidence 
from Yeast modelling; work of Dr Claudia Donnini and her team), to the original case of 
MLASA that was first described in the mid-1970s (Rawles and Weller, 1974). These findings 
expand the clinical spectrum in YARS2-related mitochondrial disease and also emphasise the 
importance of cardiac and respiratory surveillance in these patients. Testing for the YARS2 
gene should be considered in patients with exercise intolerance and multiple respiratory chain 
deficiencies in muscle biopsy, irrespective of ethnicity or absence of any of the individual 
clinical features MLASA syndrome. 
 
2.6 Expanding clinical phenotypes of an uncommon, heteroplasmic mutation in MT-ND5 
Rare pathogenic mtDNA variants impose challenges on genetic counselling and often there 
are only single case reports to inform clinical decision. This case series began with a female 
patient in her late twenties who presented with progressive ataxia and found to have the 
m.13094T>C mutation. I was intrigued by the presence of a unilateral thalamic lesion on her 
brain imaging. Such finding was rather unusual in mitochondrial disease, and the patient’s 
clinical feature was not similar to three other previously reported cases. I sought to determine 
the spectrum of clinical and imaging findings of this mutation. Altogether, I identified 15 
patients from eight pedigrees from our diagnostic database and collaboration with other 
centres outside the UK. I delineated the heterogeneities in the clinical presentation associated 
with the m.13094T>C mutation and more importantly, I also showed that thalamic lesion 
without striatal abnormality is a common finding in this mutation.
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3.1 Mitochondrial disease: genetics and management 
 
Ng, Y.S. and Turnbull, D.M. (2016) 'Mitochondrial disease: genetics and management', J 
Neurol, 263(1), pp. 179-91. 
 
3.2 Epilepsy due to mutations in the mitochondrial polymerase gamma (POLG) gene: A 
clinical and molecular genetic review   
 
Anagnostou, M.E., Ng, Y.S., Taylor, R.W. and McFarland, R. (2016) 'Epilepsy due to 
mutations in the mitochondrial polymerase gamma (POLG) gene: A clinical and molecular 
genetic review', Epilepsia, 57(10), pp. 1531-1545. 
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4.1 Sudden adult death syndrome in m.3243A>G-related mitochondrial disease: an 
unrecognized clinical entity in young, asymptomatic adults 
 
Ng, Y.S., Grady, J.P., Lax, N.Z., Bourke, J.P., Alston, C.L., Hardy, S.A., Falkous, G., 
Schaefer, A.G., Radunovic, A., Mohiddin, S.A., Ralph, M., Alhakim, A., Taylor, R.W., 
McFarland, R., Turnbull, D.M. and Gorman, G.S. (2016b) 'Sudden adult death syndrome in 
m.3243A>G-related mitochondrial disease: an unrecognized clinical entity in young, 
asymptomatic adults', Eur Heart J, 37(32), pp. 2552-9. 
 
4.2 Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination 
 
Ng, Y.S., Feeney, C., Schaefer, A.M., Holmes, C.E., Hynd, P., Alston, C.L., Grady, J.P., 
Roberts, M., Maguire, M., Bright, A., Taylor, R.W., Yiannakou, Y., McFarland, R., Turnbull, 
D.M. and Gorman, G.S. (2016) 'Pseudo-obstruction, stroke, and mitochondrial dysfunction: A 
lethal combination', Ann Neurol. doi: 10.1002/ana.24736 
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5.1 Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders 
in Mitochondrial Disease. 
 
Martikainen, M.H., Ng, Y.S., Gorman, G.S., Alston, C.L., Blakely, E.L., Schaefer, A.M., 
Chinnery, P.F., Burn, D.J., Taylor, R.W., McFarland, R. and Turnbull, D.M. (2016) 'Clinical, 
Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial 
Disease', JAMA Neurol, 73(6), pp. 668-74. 
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6.1 The clinical, biochemical and genetic features associated with RMND1-related 
mitochondrial disease 
 
Ng, Y.S., Alston, C.L., Diodato, D., Morris, A.A., Ulrick, N., Kmoch, S., Houstek, J., 
Martinelli, D., Haghighi, A., Atiq, M., Gamero, M.A., Garcia-Martinez, E., Kratochvilova, 
H., Santra, S., Brown, R.M., Brown, G.K., Ragge, N., Monavari, A., Pysden, K., Ravn, K., 
Casey, J.P., Khan, A., Chakrapani, A., Vassallo, G., Simons, C., McKeever, K., O'Sullivan, 
S., Childs, A.M., Ostergaard, E., Vanderver, A., Goldstein, A., Vogt, J., Taylor, R.W. and 
McFarland, R. (2016) 'The clinical, biochemical and genetic features associated with 
RMND1-related mitochondrial disease', J Med Genet. doi: 10.1136/jmedgenet-2016-103910 
 
6.2 Clinical features, molecular heterogeneity and prognostic implications in YARS2-
related mitochondrial myopathy 
 
Sommerville, E.W.,* Ng, Y.S.,* Alston, C.L.,* Dallabona, C., Gilberti, M., He, L., Knowles, 
C.,  Chin, S.L., Schaefer, A.M., Falkous, G., Murdoch, D., Longman, C., de Visser, M., 
Bindoff, L.A., Rawles, J.M., Dean, J.C.S., Petty, R.K., Farrugia, M.E., Haack, T.B., Prokisch, 
H., McFarland, R., Turnbull, D.M., Donnini, C., Taylor, R.W., Gorman, G.S. 
 
(* Joint first author, accepted in JAMA Neurology on 25 Aug 2016) 
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7.1 Refractory seizures, spinocerebellar ataxia and optic atrophy caused by the 
m.13094T>C mutation  
Ng, Y.S., Lax, N.Z., Maddison, P., Alston, C.L., Blakely, E.L., Hepplewhite, P.D., Riordan, 
G., Meldau, S., Chinnery, P.F., Pierre, G., Chronopoulou, E., Du, A., Hughes, I., Morris, 
A.M., Kamakari, S., Chrousos, G., Rodenburg, R.J., Saris, C.G.J., Feeney, C., Hardy, S.A.,  
Schaefer, A.M., Mundy, H., Champion, M.P., Turnbull, D.M., Taylor, R.W., McFarland, R.,  
Gorman, G.S. 
 
(This additional material is relevant to thesis but awaiting publication.) 
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Mitochondrial disease is clinically, biochemically and genetically heterogeneous and can 
affect any age group and any organ. A recent epidemiological study based on the North East 
England population has shown that the prevalence of mitochondrial disease is at least 1 in 
4300 (Gorman et al., 2015), making it as one of the most common forms of inherited muscle 
disease. The diagnostic challenge in mitochondrial disease is being addressed with better 
awareness and recognition of the clinical entity, and perhaps more so with significant 
advancements in diagnostic approaches, particularly with the application of next generation 
sequencing. However, there remain several outstanding, unmet needs for the patients. First, 
the natural history of disease progression and prognostic factors are not well characterised, 
and many uncertainties remain about genetic counselling and discussion on disease trajectory. 
Second, clinical management of many mitochondrial disorders vary between centres and 
countries; yet standards of medical care have not been established in a routine clinical setting. 
And lastly, effective treatment targeting mitochondrial dysfunction remains unavailable for 
most types of mitochondrial disorders.   
Many classic syndromes have been described in mitochondrial disease. The distinctive nature 
of these syndromes improves the recognition and diagnosis of mitochondrial disease. 
However, it is increasingly clear that only small portions of patients develop full syndromic 
presentations (Liang et al., 2014). Furthermore, our current understanding or perception of 
natural history in different genetic forms of mitochondrial disease may be biased towards the 
severe disease end or those with classic syndromes, which may be unhelpful or potentially 
misleading. A cohort-based observational study is, therefore, necessary to clarify the 
heterogeneities associated with the same mutation and may facilitate the interrogation of the 
natural history of individual mutations using standardised assessment and longitudinal data 
(Schaefer et al., 2006). Based on data derived from the Mitocohort in Newcastle, I have 
expanded on our understanding of two clinical features, namely, sudden adult death syndrome 
(SADS) (Ng et al., 2016c) and severe intestinal pseudo-obstruction (Ng et al., 2016b), which 
have been under-recognized in m.3243A>G-related mitochondrial disease, the most common 
mitochondrial DNA mutation that accounts for nearly a third of all adult cases of 
mitochondrial disease (Gorman et al., 2015). These findings helped inform and facilitate an 
update of the existing Newcastle cardiac guidelines, with the incorporation of cardiac risk 
stratification in individuals who harbour the m.3243A>G mutation. More extensive 
investigations such as cardiac MR and implantable cardiac monitoring (LinQ device) are 
being introduced as part of a pilot study for high-risk individuals.  
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The detrimental effects of chronic, excessive alcohol intake to the heart are well-established: 
cardiomyopathy (Piano, 2002), heart failure (Klatsky et al., 2005), malignant ventricular 
arrhythmia (Guzzo-Merello et al., 2015) and increased incidence of sudden cardiac death 
(Wannamethee and Shaper, 1992; Fauchier et al., 2000; Wu et al., 2015). Whilst acute 
alcohol intake have also been associated with sudden unexpected death (Penttila et al., 1989; 
Perkiomaki et al., 2016), the precise mechanism is less clear, and it is hypothesised that 
alcohol triggered the electrical instability in these patients (Perkiomaki et al., 2016). Studies 
have shown that 13-17% of patients with the m.3243A>G mutation are at risk of developing 
ventricular pre-excitation and Wolff-Parkinson-White syndrome (WPW) (Sproule et al., 
2007; Malfatti et al., 2013). WPW may deteriorate to malignant arrhythmia such as 
ventricular fibrillation in some individuals, therefore there is an increased lifetime risk of 
sudden death (Pappone et al., 2012; Kim and Knight, 2016). It is tempting to speculate that 
our patients had an undiagnosed cardiac arrhythmia that was triggered by the combination of 
acute alcohol intake, dehydration and lactic acidemia; the increase of susceptibility to these 
factors might be related to the widespread mitochondrial dysfunction in the cardiomyocytes. 
More recently, sudden unexpected cardiac deaths were reported in some patients with the 
deficiency of the mitochondrial inorganic pyrophosphatase due to recessive mutations in 
PPA2 and exquisite sensitivity to ethanol (levels of alcohol intake reported to be <0.1g and 
10g respectively in two deaths; one unit of alcohol (UK) is equivalent of 8g of pure alcohol) 
was observed (Kennedy et al., 2016). The link between alcohol metabolism and inorganic 
pyrophosphatase function has been implicated (Kennedy et al., 2016). 
The findings of SADS and the high number of cardiac deaths reported in the literature 
(Klopstock et al., 1999; Majamaa-Voltti et al., 2002; Kaufmann et al., 2011; Malfatti et al., 
2013)  provides compelling evidence regarding the importance of family tracing and the need 
for cardiac surveillance irrespective of disease status in the m.3243A>G mutation. 
Appropriate counselling prior to the predictive genetic testing for the m.3243A>G mutations 
should be offered to maternal family members. The implications of long-term surveillance for 
other complications such as gut dysmotility, sensorineural deafness, renal involvement and 
diabetes mellitus should be discussed. The identification of disease manifestation at the 
earliest stage would enable prompt medical interventions, therefore preserving overall health, 
delaying or circumventing the development of potentially fatal complications such as 
hypertrophic cardiomyopathy and intestinal pseudo-obstruction. From the perspective of 
natural history study, longitudinal follow up of these individuals would provide prospective 
data on the progression of asymptomatic stage to affected status, which has important 
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implications for health economics and resource planning. These data may also serve as one of 
the important end points for any future disease-modifying treatment.  
Gastrointestinal symptoms are common among patients harbouring the m.3243A>G mutation 
(Mancuso et al., 2013a; de Laat et al., 2015) and severe gut dysmotility manifesting as severe 
IPO has been reported. My analysis of our cohort data showed that IPO affected 1 in 8 (13%) 
individuals carrying the m.3243A>G mutation (Ng et al., 2016b). I estimated that the 
prevalence of combined IPO and m.3243A>G mutation is 1 in 200,000, and is far more 
common than the estimated prevalence of MNGIE which is typically associated with 
recurrent IPO, at 0.15 per 1,0000,000 (D'Angelo et al., 2016). I identified several risk factors 
for the development of IPO including stroke-like episodes, cardiomyopathy, low body mass 
index and high urinary mutation load. Furthermore, I was able to establish that the prompt 
recognition and medical treatment of IPO were of paramount importance in clinical practice; 
with delayed treatment or inappropriate surgical intervention leading to prolonged metabolic 
crisis and even death. These findings have reshaped our clinical care and the development of 
Newcastle gastrointestinal screening and management guidelines. 
Working at the Wellcome Trust Centre for Mitochondrial Research, one of the most 
challenging clinical queries that we often encounter is the management of super-refractory 
epilepsy associated with POLG mutations. Alpers syndrome, characterised by intractable 
seizures, psychomotor retardation and hepatic dysfunction, was commonly described as an 
infantile/early childhood disease caused by mutations in the POLG gene. However, we have 
been involved in the clinical management of several cases of teenage-onset Alpers syndrome 
with mixed outcomes over the last five years. Such observations motivated me to perform a 
systematic review of POLG-related epilepsy to determine any potential prognostic factors in 
these patients and current guidance on seizure management (Anagnostou et al., 2016). We 
identified the onset of POLG-related epilepsy clustered in two age categories (<5 years and 
teenage); with females generally having a later disease onset (the median difference between 
genders is four years). Disease onset and severity was influenced by the location of 
pathogenic variants in the gene: homozygous p.Ala467Thr and homozygous p.Trp748Ser 
mutations were generally associated with longer survivals compared to compound 
heterozygous mutations (e.g. p.Ala467Thr and p.Gly848Ser). POLG-related epilepsy often 
has an explosive onset and is relentlessly progressive. The management of POLG-related 
epilepsy remains super-refractory to conventional pharmacology therapy, and anecdotal 
evidence of individual efficacious treatments from single case reports warrants further 
investigation. We suspect a more rapid escalation of anti-seizure management, even when 
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patients only present with focal seizures, may improve outcome. A new avenue such as 
transcranial direct stimulation may deserve further exploration because it may represent a safe 
adjunctive therapy in epilepsy (San-Juan et al., 2015). I have been involved in a case recently 
in which transcranial direct stimulation was used to control refractory EPC in a teenage 
patient with mutations in POLG, with promising effect (Publication in preparation).  
The MitoCohort provides a unique opportunity to investigate genotype-phenotype overlaps. 
For example, extrapyramidal movement disorders have been identified in just over 5% of 
patients in the MitoCohort with dystonia and Parkinsonism, the most common extrapyramidal 
findings in our paediatric and adult populations, respectively (Martikainen et al., 2016). I 
identified dystonia was frequently associated with Leigh syndrome, which was caused by 
either mutation in mtDNA or nuclear genes. On the other hand, Parkinsonism was most 
commonly associated with mutations in the POLG gene. Although most of these 
extrapyramidal features were not apparent at the outset of the disease, they are progressively 
debilitating, and their response to standard pharmacotherapy such as dopamine was mixed, 
and often could not be predicted. These genotype-phenotype correlates may guide genetic 
testing for anyone with suspected mitochondrial disease in the non-specialist clinic; but also 
alert clinicians to actively screen and manage specific movement disorders associated with the 
relevant genotype. Further research into the mechanisms of these extrapyramidal movement 
disorders is necessary to find better treatment options in these patients. 
The use of whole exome sequencing (WES) in the research setting has identified new genes 
and provided more genetic diagnoses in mitochondrial disease. For example, several 
intriguing clinical syndromes with apparent tissue-specific involvement have been described 
in various mitochondrial amino-acyl tRNA synthetases (Diodato et al., 2014). However, the 
number of cases and families harbouring individual genetic mutations are often small, and 
further validation of these clinical entities and their natural histories is required with larger 
case series, through multi-centre collaboration. The YARS2 gene encoding for mitochondrial 
tyrosyl-tRNA synthetase was proposed as a second genetic cause of myopathy, lactic acidosis 
and sideroblastic anaemia (MLASA) syndrome (Riley et al., 2010), following the discovery 
of PUS1 gene (Bykhovskaya et al., 2004). In our centre, we initially identified two patients 
who harboured mutations in the YARS2 gene: a Lebanese patient with typical MLASA 
syndrome and a Scottish patient with only myopathy and lactic acidosis. Through the review 
of case notes of a deceased Scottish patient who was originally referred to our centre in the 
early 1990s, I identified a third patient with MLASA syndrome, which in fact was the first 
case of MLASA syndrome originally described in the mid-1970s (Rawles and Weller, 1974). 
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The 4th case was most intriguing, as she was a 73 year old Scottish woman that presented with 
slowly progressive myopathy without lactic acidosis or sideroblastic anaemia. I compiled the 
case series, together with previously reported cases and showed that the triad of MLASA was 
only identified in approximately 70% of patients. Furthermore, the identification of three 
Scottish families highlights that the mutations in YARS2 are not unique to ethnicities of the 
Middle East. I showed that severe cardio-respiratory involvement is evident in nearly 50% of 
cases that highlights the importance of active multi-specialist surveillance and treatment, in 
liaison with a cardiologist and respiratory physician. 
Heteroplasmic mutations in the mtDNA are often associated with diverse clinical 
manifestations, as clearly illustrated in the case series of patients harbouring the m.13094T>C 
MTND5 mutation. This mutation exhibits highly heterogeneous neurological manifestations 
including LS, MELAS/LS, spinocerebellar ataxia (SCA) with and without epileptic 
encephalopathy and LHON, and may mimic other neurological disorders such as 
demyelinating disease and SCA. Furthermore, useful pointers suggestive of a primary 
mitochondrial DNA disease such as maternal family history and abnormal muscle biopsy are 
often not identified in this uncommon mutation. Again, primary mtDNA disease can only be 
reliably excluded by performing whole mitochondrial genome sequencing in relevant clinical 
tissues given marked tissue segregation, as observed in the m.13094T>C mutation, may be 
evident. 
 
The RMND1 gene that encodes for Required for Meiotic Nuclear Division protein 1, has been 
linked to a mitochondrial translational defect and combined respiratory chain deficiencies 
(Janer et al., 2012). RMND1 deficiency was initially described in severe, neonatal onset 
encephalomyopathy but subsequently, in patients with renal impairment and deafness (Janer 
et al., 2015). To better delineate the clinical spectrum of RMND1 deficiency and inform 
clinical management, I led a multi-centre collaboration to collate clinical, biochemical and 
molecular genetics data (Ng et al., 2016a). Whilst disease onset in all patients with mutations 
in RMND1 gene was under two years (n=32), phenotypic expression and clinical outcomes 
were vastly heterogeneous. One of the striking findings was two-thirds of patients had 
evidence of kidney disease such as chronic renal impairment, secondary hypertension, 
dysplastic kidneys and renal tubular acidosis type 4. Another interesting observation was 
brady-arrhythmia only identified in patients of Pakistani origin with homozygous founder 
mutations. Patients with renal impairment had a better survival compared to those without 
renal impairment (the latter patients had CNS involvement primarily). The longer survival 
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may be attributable to the availability of active, supportive treatments such as correction of 
electrolytes, dialysis and renal transplant (n=4) (Parikh et al., 2016) which have been 
instigated. Meticulous clinical phenotyping of rare mitochondrial disease remains crucial to 
guiding clinical management and surveillance for treatable complications, as exemplified by 
our findings in the case series of RMND1 deficiency. 
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Conclusions 
The central theme of this thesis was to characterise the spectrum of clinical phenotypes 
further and identify complications that may be amenable to therapy with better clinical 
surveillance in patients with mitochondrial disease caused by mtDNA and nDNA mutations. I 
have demonstrated a connection between SADS and asymptomatic individuals with the 
m.3243A>G mutation, and highlighted that active family screening irrespective of disease 
status and proposed a simple risk stratification tool to tailor a strategy for cardiac surveillance 
and treatment accordingly. I have identified a high prevalence of IPO in m.3243AG- related 
mitochondrial disease and devised the Newcastle Gastrointestinal screening and management 
guidelines to streamline clinical practice based on these findings. Using the Mitocohort data, I 
have shown that dystonia and Parkinsonism are two common extrapyramidal movement 
disorders in patients, whose clinical management remains challenging. I have expanded the 
clinical features associated with YARS2 mutation and highlighted that the typical MLASA 
syndrome was not essential to the clinical diagnosis. I have also identified that cardio-
respiratory involvement is prominent and a common cause of death in patients with YARS2 
mutations, and suggested prompt recognition and supportive treatment may delay disease 
progression. Renal involvement is another example of a treatable complication that I have 
identified in a cohort of patients associated with RMND1 deficiency. Aggressive management 
is warranted, in such cases, as I have shown that a subgroup of patients with kidney 
involvement had a better long-term survival. These findings will serve to provide robust data 
on the delineation of natural history and prognostication in mitochondrial disease; and more 
importantly, will aid to set the standard for clinical care and help inform and develop 
nationally-endorsed clinical management guidelines for patients with mitochondrial disease 
whilst the hunt for a cure continues. 
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Future work 
(1) Potential for future research and preventative and early treatments in intestinal pseudo-
obstruction 
Unpublished data from the MRC Mitochondrial Disease Patient Cohort (Newcastle) show that 
over 70% of patients with the m.3243A>G mutation have variable degrees of GI symptoms, 
corroborated with the previous reports (Kaufmann et al., 2011; de Laat et al., 2015). Intestinal 
pseudo-obstruction is at the end of the spectrum of gut dysmotility, and it is intuitive to 
hypothesise that early and aggressive treatment of chronic constipation may reduce the risk or 
prevent the development of IPO. Current evidence suggests a role for smooth muscle 
involvement (high mutant heteroplasmy levels and COX deficiency) in the development of 
gut dysmotility among patients with the m.3243A>G mutation (Betts et al., 2008). However, 
the role of the enteric nervous system has not been investigated extensively. It is possible that 
bacterial overgrowth plays an important part in the development of recurrent pseudo-
obstruction given that gas filled dilated loops of bowel are frequently observed on imaging. 
Interrogation of the gut microbiome in those individuals affected by IPO and stroke-like 
episodes and those who are unaffected might further elucidate the mechanism of ‘neuro-
gastrointestinal crisis’ given that at least 50% of patients presented with acute metabolic 
stroke also developed IPO concurrently. In addition, systematic evaluation of dietary 
intervention such as low residue diet and probiotics, and antimicrobial therapy for bacterial 
overgrowth in these patients are warranted.  
 
(2) Future research on neuro-radiological techniques for specific genetic defects 
Neuroimaging is an essential tool for the diagnosis of mitochondrial disease with predominant 
CNS involvement, but it remains under-utilized in clinical research. Several studies showed 
that MR spectroscopy appeared to be a useful biomarker on identifying individuals with the 
m.3243A>G mutation who were at risk of developing stroke-like episodes (Abe et al., 2004; 
Weiduschat et al., 2014). However, such findings need to be replicated in larger, prospective 
studies before translating into routine clinical practice and other mtDNA mutations such as 
MTND5 should also be investigated. Stroke-like episodes with a preferential involvement of 
posterior cerebral cortex are enigmatic in primary mtDNA disease and POLG-related 
disorders. Functional MR and positron emission tomography (PET) scans would be useful on 
interrogating the cellular metabolism in different brain regions of patients with mitochondrial 
Future Work 
90 
 
disease in vivo. Tractography, a 3D-modelling MRI technique, can be applied to investigate 
the roles of white matter and brain circuits in seizure propagation, given the spreading of 
stroke-like lesions is believed to be driven primarily by the neuronal hyper-excitability (Iizuka 
et al., 2002; Iizuka et al., 2003).  
Cognitive impairment and ataxia are clinical features commonly found in patients at their later 
stage of the mitochondrial disease. The imaging findings of cerebral and cerebellar atrophy 
together with low brain weight and evidence of neuronal loss in post-mortem studies strongly 
suggest an active neurodegenerative process in mitochondrial disease, irrespective of 
genotype. Brain volumetric study can provide quantitative data on investigating the extent and 
rate of atrophy, which may serve as an important biomarker and outcome measure in future 
drug trials.  
 
(3) Explore genotype/phenotype correlation for identifying more accurate prognostic 
markers. 
A large patient number is essential for exploring genotype-phenotype correlation, identifying 
and validating putative prognostic factors that are relevant in clinical practice. The 
establishment of the national patient registry in the UK, Italy, Germany, United States and 
Australia is a significant development towards a better understanding of the natural history of 
mitochondrial disease caused by different genetic defects over the last decade. Several studies 
derived from these national cohort data have further defined the clinical phenotypes of 
prevalent mutations such as m.3243A>G (Mancuso et al., 2013a; Nesbitt et al., 2013), 
m.8344A>G (Mancuso et al., 2013b; Altmann et al., 2016) and single, large scale mtDNA 
deletion (Grady et al., 2014; Mancuso et al., 2015), and provided a more objective and in-
depth evaluation of the spectrum of disease burden in these patients when compared to early 
case reports and small case series. Standardisation of clinical assessment and harmonisation of 
data collection such as using human phenotype ontology terms between these national 
registries would allow pooling clinical data for robust analysis. More importantly, 
international collaboration should help to establish consensus guidance, especially on 
surveillance for complications and treatment, prioritise areas of clinical research and recruit 
patients to future drug trials.
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